US20100092471A1 - Porphyromonas Gingivalis Polypeptides Useful in the Prevention of Periodontal Disease - Google Patents
Porphyromonas Gingivalis Polypeptides Useful in the Prevention of Periodontal Disease Download PDFInfo
- Publication number
- US20100092471A1 US20100092471A1 US12/306,495 US30649507A US2010092471A1 US 20100092471 A1 US20100092471 A1 US 20100092471A1 US 30649507 A US30649507 A US 30649507A US 2010092471 A1 US2010092471 A1 US 2010092471A1
- Authority
- US
- United States
- Prior art keywords
- amino acid
- acid sequence
- seq
- gingivalis
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 241000605862 Porphyromonas gingivalis Species 0.000 title claims abstract description 112
- 208000028169 periodontal disease Diseases 0.000 title claims abstract description 39
- 230000002265 prevention Effects 0.000 title claims abstract description 13
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 111
- 102000004196 processed proteins & peptides Human genes 0.000 title claims description 89
- 229920001184 polypeptide Polymers 0.000 title claims description 69
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 181
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 155
- 238000000034 method Methods 0.000 claims abstract description 57
- 239000000203 mixture Substances 0.000 claims abstract description 42
- 238000011282 treatment Methods 0.000 claims abstract description 14
- 150000001413 amino acids Chemical class 0.000 claims description 46
- 239000003937 drug carrier Substances 0.000 claims description 9
- 230000028993 immune response Effects 0.000 claims description 9
- 241000283690 Bos taurus Species 0.000 claims description 4
- 241000282472 Canis lupus familiaris Species 0.000 claims description 2
- 241000283086 Equidae Species 0.000 claims description 2
- 241000282326 Felis catus Species 0.000 claims description 2
- 241000282412 Homo Species 0.000 claims description 2
- 241001494479 Pecora Species 0.000 claims description 2
- 241000282887 Suidae Species 0.000 claims description 2
- 244000144977 poultry Species 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 28
- 210000004027 cell Anatomy 0.000 abstract description 57
- 150000003278 haem Chemical class 0.000 abstract description 32
- 229960005486 vaccine Drugs 0.000 abstract description 30
- 102000007456 Peroxiredoxin Human genes 0.000 abstract description 5
- 108030002458 peroxiredoxin Proteins 0.000 abstract description 5
- 230000001105 regulatory effect Effects 0.000 abstract description 5
- 108090001030 Lipoproteins Proteins 0.000 abstract description 4
- 102000004895 Lipoproteins Human genes 0.000 abstract description 4
- 235000018102 proteins Nutrition 0.000 description 143
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 28
- 238000004458 analytical method Methods 0.000 description 24
- 230000012010 growth Effects 0.000 description 24
- 101000993469 Homo sapiens Beta-catenin-interacting protein 1 Proteins 0.000 description 21
- 102100031680 Beta-catenin-interacting protein 1 Human genes 0.000 description 20
- 150000002500 ions Chemical class 0.000 description 20
- 230000000890 antigenic effect Effects 0.000 description 19
- 239000000499 gel Substances 0.000 description 17
- 241000894006 Bacteria Species 0.000 description 16
- 239000002671 adjuvant Substances 0.000 description 16
- 108010026552 Proteome Proteins 0.000 description 15
- 230000014509 gene expression Effects 0.000 description 14
- 229910052742 iron Inorganic materials 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 230000027455 binding Effects 0.000 description 12
- 239000012634 fragment Substances 0.000 description 12
- 230000009545 invasion Effects 0.000 description 12
- 241000335876 Porphyromonas gingivalis W50 Species 0.000 description 11
- 230000029087 digestion Effects 0.000 description 11
- 239000000427 antigen Substances 0.000 description 10
- 108091007433 antigens Proteins 0.000 description 10
- 102000036639 antigens Human genes 0.000 description 10
- 238000013459 approach Methods 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 229940024606 amino acid Drugs 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 108020004705 Codon Proteins 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 210000002919 epithelial cell Anatomy 0.000 description 8
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 7
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 7
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 7
- 239000001099 ammonium carbonate Substances 0.000 description 7
- 239000005557 antagonist Substances 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 230000002452 interceptive effect Effects 0.000 description 7
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 7
- 201000001245 periodontitis Diseases 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 102000035195 Peptidases Human genes 0.000 description 6
- 108091005804 Peptidases Proteins 0.000 description 6
- 102000004142 Trypsin Human genes 0.000 description 6
- 108090000631 Trypsin Proteins 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- 210000000988 bone and bone Anatomy 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- BTIJJDXEELBZFS-UHFFFAOYSA-K hemin Chemical compound [Cl-].[Fe+3].[N-]1C(C=C2C(=C(C)C(C=C3C(=C(C)C(=C4)[N-]3)C=C)=N2)C=C)=C(C)C(CCC(O)=O)=C1C=C1C(CCC(O)=O)=C(C)C4=N1 BTIJJDXEELBZFS-UHFFFAOYSA-K 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 238000002372 labelling Methods 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 210000004379 membrane Anatomy 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 239000012588 trypsin Substances 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- -1 Leu Chemical group 0.000 description 5
- 108010052285 Membrane Proteins Proteins 0.000 description 5
- 108700026244 Open Reading Frames Proteins 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000007613 environmental effect Effects 0.000 description 5
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 5
- 208000007565 gingivitis Diseases 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 230000002163 immunogen Effects 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000000159 protein binding assay Methods 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 241000700618 Vaccinia virus Species 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000004709 cell invasion Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 210000002808 connective tissue Anatomy 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 102000006240 membrane receptors Human genes 0.000 description 4
- 108020004084 membrane receptors Proteins 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000004885 tandem mass spectrometry Methods 0.000 description 4
- 230000001018 virulence Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 208000023514 Barrett esophagus Diseases 0.000 description 3
- 102000014914 Carrier Proteins Human genes 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 108010059378 Endopeptidases Proteins 0.000 description 3
- 102000005593 Endopeptidases Human genes 0.000 description 3
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 3
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 241000986839 Porphyromonas gingivalis W83 Species 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 239000000589 Siderophore Substances 0.000 description 3
- 230000006978 adaptation Effects 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000002238 attenuated effect Effects 0.000 description 3
- 244000052616 bacterial pathogen Species 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000037149 energy metabolism Effects 0.000 description 3
- 230000029578 entry into host Effects 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 230000009368 gene silencing by RNA Effects 0.000 description 3
- 238000009650 gentamicin protection assay Methods 0.000 description 3
- 210000001648 gingival epithelial cell Anatomy 0.000 description 3
- 230000034659 glycolysis Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 230000036542 oxidative stress Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 235000019833 protease Nutrition 0.000 description 3
- 238000000575 proteomic method Methods 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 229960004854 viral vaccine Drugs 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 101100445523 Bacteroides fragilis ermF gene Proteins 0.000 description 2
- 108700010070 Codon Usage Proteins 0.000 description 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
- 238000000018 DNA microarray Methods 0.000 description 2
- 208000002064 Dental Plaque Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108010021582 Glucokinase Proteins 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 241000976924 Inca Species 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 108010006444 Leucine-Rich Repeat Proteins Proteins 0.000 description 2
- 241000186779 Listeria monocytogenes Species 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241001467552 Mycobacterium bovis BCG Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 101710116435 Outer membrane protein Proteins 0.000 description 2
- 108010033276 Peptide Fragments Proteins 0.000 description 2
- 102000007079 Peptide Fragments Human genes 0.000 description 2
- 101000992168 Porphyromonas gingivalis (strain ATCC BAA-308 / W83) Outer membrane protein 40 Proteins 0.000 description 2
- 101001086534 Porphyromonas gingivalis (strain ATCC BAA-308 / W83) Outer membrane protein 41 Proteins 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 108091030071 RNAI Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108010008038 Synthetic Vaccines Proteins 0.000 description 2
- 208000008312 Tooth Loss Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 2
- 229960001212 bacterial vaccine Drugs 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 230000026502 entry into host cell Effects 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 2
- 150000002505 iron Chemical class 0.000 description 2
- 210000004901 leucine-rich repeat Anatomy 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
- 230000005923 long-lasting effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000011785 micronutrient Substances 0.000 description 2
- 235000013369 micronutrients Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 210000002200 mouth mucosa Anatomy 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000003239 periodontal effect Effects 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 235000019419 proteases Nutrition 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000009711 regulatory function Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 238000005199 ultracentrifugation Methods 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- PBVAJRFEEOIAGW-UHFFFAOYSA-N 3-[bis(2-carboxyethyl)phosphanyl]propanoic acid;hydrochloride Chemical compound Cl.OC(=O)CCP(CCC(O)=O)CCC(O)=O PBVAJRFEEOIAGW-UHFFFAOYSA-N 0.000 description 1
- 101710092702 47 kDa protein Proteins 0.000 description 1
- 102000005416 ATP-Binding Cassette Transporters Human genes 0.000 description 1
- 108010006533 ATP-Binding Cassette Transporters Proteins 0.000 description 1
- 208000035657 Abasia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000002679 Alveolar Bone Loss Diseases 0.000 description 1
- 244000105975 Antidesma platyphyllum Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- KSFOVUSSGSKXFI-GAQDCDSVSA-N CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O Chemical group CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O KSFOVUSSGSKXFI-GAQDCDSVSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000253373 Caldanaerobacter subterraneus subsp. tengcongensis Species 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- XONQIEHAMZZCGB-UHFFFAOYSA-N Cl.Cl.Cl.NCC(O)=O Chemical compound Cl.Cl.Cl.NCC(O)=O XONQIEHAMZZCGB-UHFFFAOYSA-N 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 108091066380 Dps family Proteins 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 102100039911 Endoplasmic reticulum transmembrane helix translocase Human genes 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 108091020100 Gingipain Cysteine Endopeptidases Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101000887230 Homo sapiens Endoplasmic reticulum transmembrane helix translocase Proteins 0.000 description 1
- 101000957351 Homo sapiens Myc-associated zinc finger protein Proteins 0.000 description 1
- 101000855256 Homo sapiens Uncharacterized protein C16orf74 Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101100490139 Mus musculus Acer3 gene Proteins 0.000 description 1
- 102100038750 Myc-associated zinc finger protein Human genes 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 208000005888 Periodontal Pocket Diseases 0.000 description 1
- 102000001105 Phosphofructokinases Human genes 0.000 description 1
- 108010069341 Phosphofructokinases Proteins 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 102000017033 Porins Human genes 0.000 description 1
- 108010013381 Porins Proteins 0.000 description 1
- 241000023506 Porphyromonas gingivalis ATCC 33277 Species 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010073443 Ribi adjuvant Proteins 0.000 description 1
- 102000002278 Ribosomal Proteins Human genes 0.000 description 1
- 108010000605 Ribosomal Proteins Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical compound OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 102100026591 Uncharacterized protein C16orf74 Human genes 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 101710149909 Zinc carboxypeptidase Proteins 0.000 description 1
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 1
- LUXUAZKGQZPOBZ-SAXJAHGMSA-N [(3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] (Z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O LUXUAZKGQZPOBZ-SAXJAHGMSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 159000000013 aluminium salts Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000009604 anaerobic growth Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- WXNRAKRZUCLRBP-UHFFFAOYSA-N avridine Chemical compound CCCCCCCCCCCCCCCCCCN(CCCN(CCO)CCO)CCCCCCCCCCCCCCCCCC WXNRAKRZUCLRBP-UHFFFAOYSA-N 0.000 description 1
- 229950010555 avridine Drugs 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000008952 bacterial invasion Effects 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000032770 biofilm formation Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000006161 blood agar Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000002789 catalaselike Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000001277 chronic periodontitis Diseases 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 229940066758 endopeptidases Drugs 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 235000021112 essential micronutrients Nutrition 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 101150024071 feoB1 gene Proteins 0.000 description 1
- 108010035554 ferric citrate iron reductase Proteins 0.000 description 1
- 108010072250 fimbrillin Proteins 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000023266 generation of precursor metabolites and energy Effects 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000009424 haa Nutrition 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 101150057506 hagA gene Proteins 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 1
- 229940025294 hemin Drugs 0.000 description 1
- 108010037896 heparin-binding hemagglutinin Proteins 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 108091069349 internalin family Proteins 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000005040 ion trap Methods 0.000 description 1
- 150000004698 iron complex Chemical class 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 101150011052 kgp gene Proteins 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 244000039328 opportunistic pathogen Species 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 230000026447 protein localization Effects 0.000 description 1
- 238000000734 protein sequencing Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000011506 response to oxidative stress Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 101150047215 rgpA gene Proteins 0.000 description 1
- 101150111442 rgpB gene Proteins 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 239000007320 rich medium Substances 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- RWVGQQGBQSJDQV-UHFFFAOYSA-M sodium;3-[[4-[(e)-[4-(4-ethoxyanilino)phenyl]-[4-[ethyl-[(3-sulfonatophenyl)methyl]azaniumylidene]-2-methylcyclohexa-2,5-dien-1-ylidene]methyl]-n-ethyl-3-methylanilino]methyl]benzenesulfonate Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C(=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C)C=2C(=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C)C=C1 RWVGQQGBQSJDQV-UHFFFAOYSA-M 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000011537 solubilization buffer Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 108091006106 transcriptional activators Proteins 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0216—Bacteriodetes, e.g. Bacteroides, Ornithobacter, Porphyromonas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/18—Dental and oral disorders
Definitions
- the present invention relates to compositions and methods of isolating Porphyromonas gingivalis ( P. gingivalis ) proteins useful in the prevention of and treatment of periodontal disease. More particularly, the invention is directed to vaccine compositions and methods based on P. gingivalis proteins identified to be regulated by haem availability that can be used in the prevention and treatment of periodontal disease.
- P. gingivalis Porphyromonas gingivalis
- Periodontal disease is a chronic bacterial infection that affects the gums and bone supporting the teeth. Periodontal disease begins when the bacteria in plaque (the sticky biofilm that constantly forms on teeth) causes the gums to become inflamed. Periodontal disease can affect the gingival tissue (gums); periodontal membrane (connective tissue embedded in the cementum and alveolar bone); cementum (mineralized connective tissue covering the roots of the teeth); and the alveolar bone (bone socket), Depending on the progression of the disease, there may occur a destruction of periodontal membranes, alveolar bone loss, and apical migration of the connective tissue attachment. Advanced periodontal disease may result in the formation of periodontal pockets harbouring bacterial plaque, and progressive loosening and eventual loss of teeth.
- Periodontal disease includes gingivitis that can advance to periodontitis.
- Chronic periodontitis is an inflammatory disease of the supporting tissues of teeth that is associated with specific bacteria in subgingival dental plaque. The disease has been estimated to affect around 35% of dentate adults and is a major cause of tooth loss in the Western world (1) .
- P. gingivalis a member of the normal oral microflora of subgingival dental plague, has been implicated as one of the major opportunistic pathogens in the progression of this disease (2) .
- P. gingivalis is a black-pigmented, asaccharolytic, Gram-negative anaerobic, cocco-bacillus, that relies on the fermentation of amino acids for energy production (3) .
- P. gingivalis has an essential growth requirement for iron that it preferentially acquires in the form of haem, a molecule comprised of a protoporphyrin IX ring (PPIX) with a co-ordinated central ferrous atom (4) .
- This utilization of haem as an iron source may reflect the inability of P. gingivalis to synthesize PPIX de novo (5) .
- Haem is preferentially obtained from haemoglobin, and is acquired through the activity of the cell-surface Arg- and Lys-specific proteinase/adhesin complex (4,6,7) , possibly in conjunction with a TonB-linked outer membrane receptor, HmuR (8) .
- P. gingivalis does not produce siderophores and lacks the ferric reductase activity usually associated with siderophore-mediated iron acquisition (9,10) .
- P. gingivalis stores haem on its surface in the form of ⁇ -oxo bis-haem, which has inherent catalase activity that helps to protect the cell from oxidative attack (11) .
- P. gingivalis to be able to compete with the large numbers and diversity of bacteria within the micronutrient-limiting environment of the oral cavity (12) it not only has to establish itself but also has to evade or overcome numerous host defenses.
- compositions which would be useful in the prevention and treatment of periodontal disease it is desirable to identify agents that interfere and prevent the initial stages of the disease process.
- the present inventors have now developed methods for identifying specific P. gingivalis proteins regulated by haem availability that can be used as suitable targets for the prevention and treatment of periodontal disease.
- the present inventors have successfully developed methods of identifying P. gingivalis proteins regulated by haem availability that are responsible for P. gingivalis metabolism, virulence and invasion of host cells.
- two specific internalin-like P. gingivalis proteins namely PG0350, PG1374 involved in the internalization of P. gingivalis by host cells, a hypothetical protein, PG1019 purported to be a cell surface lipoprotein and an alkyl hydroperoxide reductase protein, PG0618 have been identified as useful targets for the prevention and treatment of periodontal disease.
- a first aspect of the invention is an isolated antigenic P. gingivalis polypeptide, the polypeptide being selected from the group consisting of:
- a second aspect of the invention is a vaccine composition for use in raising an immune response directed against P. gingivalis in a subject, the composition comprising an effective amount of at least one polypeptide of the first aspect of the invention and a pharmaceutically acceptable carrier.
- a third aspect of the invention is a method of preventing or treating a subject for periodontal disease comprising administering to the subject a vaccine composition according to the present invention.
- a fourth aspect of the invention is an antibody raised against a polypeptide of the first aspect of the present invention.
- the antibody binds specifically to the polypeptides of the present invention.
- a fifth aspect of the invention is a composition useful in the prevention or treatment of periodontal disease, the composition comprising an antibody of the fourth aspect of the present invention and a pharmaceutically acceptable carrier.
- a method of identifying a P. gingivalis polypeptide involved in the progression of periodontal disease comprising the steps of:
- step a) determining the relative amount of a polypeptide or peptide thereof produced by P. gingivalis grown under haem limited conditions; and b) determining the relative amount of the polypeptide or peptide thereof produced by P. gingivalis grown under higher haem conditions than step a); wherein an increase in the amount of the polypeptide or peptide fragment thereof detected in step a) compared to step by indicates that the polypeptide is involved in the progression of periodontal disease.
- an interfering RNA molecule comprising a double stranded region of at least 19 base pairs in each Strand wherein one of the strands of the double stranded region is complementary to a region of SEQ ID NO: 5 or SEQ ID NO: 6 or SEQ ID NO; 7 or SEQ ID NO: 8.
- an eighth aspect of the present invention there is provided for the use of at least one polypeptide of the first aspect of the present invention in the manufacture of a medicament for the treatment of periodontal disease in a subject.
- FIG. 1 shows a diagrammatic representation of the combined strategy used to identify proteins from P. gingivalis grown under haem-limitation.
- the lysed cells were prefractionated into soluble and insoluble fractions using ultra-centrifugation, followed by analysis of these two fractions.
- the separation and analysis procedure consists of two main methods; LCMS with gas phase fractionation and geLCMS.
- FIG. 2 shows a graph indicating the codon adaptation index (CAI) distribution of the identified P. gingivalis proteome and the predicted P. gingivalis genome calculated using INCA (14) .
- CAI codon adaptation index
- FIG. 3 shows the analysis and identification of PG0390 based on detection of a single peptide
- A Total ion chromatogram.
- B Mass spectrum at 54.8 min, insert showing an enlarged ICAT peptide ion pair at 703.9 and 708.4 m/z of ratio 1:2 (L/H).
- FIG. 4 shows the distribution of protein abundance based on ratio of haem-limitation over haem-excess (every one unit on the Log 2 scale indicates a two fold change).
- FIG. 5 shows binding to KB cells by P. gingivalis W50 ( ⁇ ) and ECR312 ( ⁇ ).
- Insert shows the gating of live KB cells based on forward and side scattering properties (top left), five peaks representing FITC fluorescence of hound P. gingivalis W50 to KB cells at P. gingivalis :KB cell ratios of 250 to 1250 (top right) and ECR312 (bottom right).
- FIG. 6 shows the amino acid sequence of PG0350 protein (referred to as SEQ ID NO:1 as also indicated in the sequence listing).
- FIG. 7 shows the amino acid sequence of PG1374 protein. (referred to as SEQ ID NO:2 as also indicated in the sequence listing).
- FIG. 8 shows the amino acid sequence of PG1019 protein (referred to as SEQ ID NO:3 as also indicated in the sequence listing).
- FIG. 9 shows the amino acid sequence of PG0618 protein (referred to as SEQ ID NO:4 as also indicated in the sequence listing).
- the present invention advantageously provides the identification of P. gingivalis proteins regulated by haem availability as useful targets for the prevention and treatment of periodontal disease.
- the invention provides the identification of P. gingivalis proteins upregulated by haem-limitation as useful targets for the prevention and treatment of periodontal disease.
- the invention provides an isolated antigenic P. gingivalis polypeptide, the polypeptide being selected from the group consisting of:
- the isolated antigenic polypeptide is 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:2 or SEQ ID NO:3 or SEQ ID NO:4.
- the isolated antigenic polypeptide comprises an amino acid sequence comprising at least 20, 30, 40, 50, 60, 70, 80, 90 or 100 amino acids identical to a contiguous amino acid sequence of SEQ ID NO:1 or SEQ ID NO:2 or SEQ ID NO:3 or SEQ ID NO:4.
- the antigenic polypeptides comprise amino acid sequences that compose the hydrophilic, surface-exposed regions of the PG1374 or PG0350 or PG1019 or PG0618 protein.
- polypeptides, proteins, and polypeptides are used interchangeably herein.
- the polypeptides of the present invention can include recombinant polypeptides such as fusion polypeptides. Methods for the production of a fusion polypeptide are well-known to those skilled in the art.
- altered polypeptides can be either naturally occurring (that is to say, purified or isolated from a natural source) or synthetic (for example, by site-directed metagenesis on the encoding DNA). It is intended that such altered polypeptides which have at least 85%, preferably at least 90%, 95%, 96%, 97%, 98% or 99% identity with the sequences set out in the Sequence Listing are within the scope of the present invention. Antibodies raised against these altered polypeptides will also bind to the polypeptides having one of the sequences set out in the Sequence Listings.
- isolated polypeptide refers to a polypeptide that has been separated from other proteins, lipids, and nucleic acids with which it naturally occurs or the polypeptide or peptide may be synthetically synthesised.
- the polypeptide is also separated from substances, for example, antibodies or gel matrix, for example, polyacrylamide, which are used to purify it.
- the polypeptide constitutes at least 10%, 20%, 50%, 70%, and 80% of dry weight of the purified preparation.
- the preparation contains a sufficient amount of polypeptide to allow for protein sequencing (i.e. at least 1, 10, or 100 mg).
- the isolated polypeptides described herein may be purified by standard techniques, such as column chromatography (using various matrices which interact with the protein products, such as ion exchange matrices, hydrophobic matrices and the like), affinity chromatography utilizing antibodies specific for the protein or other ligands which bind to the protein.
- an “antigenic polypeptide” used herein is a moiety, such as a polypeptide, analog or fragment thereof, that is capable of binding to a specific antibody with sufficiently high affinity to form a detectable antigen-antibody complex.
- the antigenic polypeptide comprises an immunogenic component that is capable of eliciting a humoral and/or cellular immune response in a host animal.
- a “contiguous amino acid sequence” as used herein refers to a continuous stretch of amino acids.
- amino acid sequence identities or similarities may be calculated using the GAP programme and/or aligned using the PILEUP programme of the Computer Genetics Group, Inc., University Research Park, Madison, Wis., United States of America (20) .
- the GAP programme utilizes the algorithm of Needleman and Wunsch (21) to maximise the number of identical/similar residues and to minimise the number and length of sequence gaps in the alignment.
- the Clustal W programme (22) is used.
- the present invention also provides a vaccine composition for use in raising an immune response directed against P. gingivalis in a subject, the composition comprising an effective amount of at least one polypeptide of the first aspect of the invention and a pharmaceutically acceptable carrier.
- the vaccine composition of the present invention preferably comprises an antigenic polypeptide that comprises at least one antigen that can be used to confer immunity against P. gingivalis .
- the subject treated by the method of the invention may be selected from, but is not limited to, the group consisting of humans, sheep, cattle, horses, bovine, pigs, poultry, dogs and cats.
- the subject is a human.
- An immune response directed against P. gingivalis is achieved in a subject, when the subject's immune system produces antibodies against the specific antigenic polypeptides.
- the vaccine composition is preferably administered to a subject to induce immunity to P. gingivalis and thereby prevent periodontal disease.
- the term “effective amount” as used herein means a dose sufficient to elicit an immune response against P. gingivalis . This will vary depending on the subject and the level of P. gingivalis infection and ultimately will be decided by the attending scientist, physician or veterinarian.
- the vaccine composition of the present invention comprises a suitable pharmaceutically-acceptable carrier, such as diluent and/or adjuvant suitable for administration to a human or animal subject.
- the vaccine preferably comprises a suitable adjuvant for delivery orally by nasal spray, or by injection to produce a specific immune response against P. gingivalis .
- a vaccine of the present invention can also be based upon a recombinant nucleic acid sequence encoding an antigenic polypeptide of the present invention, wherein the nucleic acid sequence is incorporated into an appropriate vector and expressed in a suitable transformed host (e.g. E. coli, Bacillus subtilis, Saccharomyces cerevisiae , COS cells, CHO cells and HeLa cells) containing the vector.
- a suitable transformed host e.g. E. coli, Bacillus subtilis, Saccharomyces cerevisiae , COS cells, CHO cells and HeLa cells
- the vaccine can be produced using recombinant DNA methods as illustrated herein, or can be synthesized chemically from the amino acid sequence described in the present invention. Additionally, according to the present invention, the antigenic polypeptides may be used to generate P. gingivalis antisera useful for passive immunization against periodontal disease and infections caused by P. gingivalis.
- adjuvants known those skilled in the art are commonly used in conjunction with vaccine formulations.
- the adjuvants aid by modulating the immune response and in attaining a more durable and higher level of immunity using smaller amounts of vaccine antigen or fewer doses than if the vaccine antigen were administered alone.
- adjuvants include incomplete Freunds adjuvant (IFA), Adjuvant 65 (containing peanut oil, mannide monooleate and aluminium monostrearate), oil emulsions, Ribi adjuvant, the pluronic polyols, polyamines, Avridine, Quil A, saponin, MPL, QS-21, and mineral gels such as aluminium salts.
- the vaccine may include conventional pharmaceutically acceptable carriers, excipients, fillers, buffers or diluents as appropriate.
- One or more doses of the vaccine containing adjuvant may be administered prophylactically to prevent periodontal disease or therapeutically to treat already present periodontal disease.
- the preparation is combined with a mucosal adjuvant and administered via the oral or nasal mute.
- mucosal adjuvants are cholera toxin and heat labile E. coli toxin, the non-toxic B sub-units of these toxins, genetic mutants of these toxins which have reduced toxicity.
- Other methods which may be utilised to deliver the antigenic polypeptides orally or nasally include incorporation of the polypeptides into particles of biodegradable polymers (such as acrylates or polyesters) by micro-encapsulation to aid uptake of the microspheres from the gastrointestinal tract or nasal cavity and to protect degradation of the proteins.
- Liposomes, ISCOMs, hydrogels are examples of other potential methods which may be further enhanced by the incorporation of targeting molecules such as LTB, CTB or lectins (mannan, chitin, and chitosan) for delivery of the antigenic polypeptides to the mucosal immune system.
- targeting molecules such as LTB, CTB or lectins (mannan, chitin, and chitosan)
- the vaccine may include conventional pharmaceutically acceptable carriers, excipients, fillers, coatings, dispersion media, antibacterial and antifungal agents, buffers or diluents as appropriate.
- Another mode of this embodiment provides for either, a live recombinant viral vaccine, recombinant bacterial vaccine, recombinant attenuated bacterial vaccine, or an inactivated recombinant viral vaccine which is used to protect against infections caused by P. gingivalis .
- Vaccinia virus is the best known example, in the art, of an infectious virus that is engineered to express vaccine antigens derived from other organisms.
- the recombinant live vaccinia virus which is attenuated or otherwise treated so that it does not caused disease by itself, is used to immunise the host. Subsequent replication of the recombinant virus within the host provides a continual stimulation of the immune system with the vaccine antigens such as the antigenic polypeptides, thereby providing long lasting immunity.
- live vaccine vectors include: adenovirus, cytomegalovirus, and preferably the poxviruses such as vaccinia (24) and attenuated salmonella strains (25-28) .
- Live vaccines are particularly advantageous because they continually stimulate the immune system which can confer substantially long-lasting immunity.
- the live vaccine itself may be used in a protective vaccine against P. gingivalis .
- the live vaccine can be based on a bacterium that is a commensal inhabitant of the oral cavity. This bacterium can be transformed with a vector carrying a recombinant inactivated polypeptide and then used to colonise the oral cavity, in particular the oral mucosa.
- the expression of the recombinant protein will stimulate the mucosal associated lymphoid tissue to produce neutralising antibodies.
- the genes encoding the polypeptides may be inserted into the vaccinia virus genomic DNA at a site which allows for expression of epitopes but does not negatively affect the growth or replication of the vaccinia virus vector.
- the resultant recombinant virus can be used as the immunogen in a vaccine formulation.
- the same methods can be used to construct an inactivated recombinant viral vaccine formulation except the recombinant virus is inactivated, such as by chemical means known in the art, prior to use as an immunogen and without substantially affecting the immunogenicity of the expressed immunogen.
- immunisation may be passive, i.e. immunisation comprising administration of purified immunoglobulin containing an antibody against a polypeptide of the present invention.
- the antigenic polypeptides used in the methods and compositions of the present invention may be combined with suitable excipients, such as emulsifiers, surfactants, stabilisers, dyes, penetration enhancers, anti-oxidants, water, salt solutions, alcohols, polyethylene glycols, gelatine, lactose, magnesium sterate and silicic acid.
- suitable excipients such as emulsifiers, surfactants, stabilisers, dyes, penetration enhancers, anti-oxidants, water, salt solutions, alcohols, polyethylene glycols, gelatine, lactose, magnesium sterate and silicic acid.
- the antigenic polypeptides are preferably formulated as a sterile aqueous solution.
- the vaccine compositions of the present invention may be used to complement existing treatments for periodontal disease.
- a third aspect of the invention is a method of preventing or treating a subject for periodontal disease comprising administering to the subject a vaccine composition according to the present invention.
- Periodontal diseases range from simple gum inflammation to serious disease that results in major damage to the soft tissue and bone that support the teeth.
- Periodontal disease includes gingivitis and periodontitis.
- Bacteria, mainly Gram-negative species including P. gingivalis cause inflammation of the gums that is called “gingivitis.” In gingivitis, the gums become red, swollen and can bleed easily. When gingivitis is not treated, it can advance to “periodontitis” (which means “inflammation around the tooth.”).
- gingivitis which means “inflammation around the tooth.”.
- gingivitis which means “inflammation around the tooth.”.
- gingivitis which means “inflammation around the tooth.”.
- gingivitis which means “inflammation around the tooth.”.
- gingivitis which means “inflammation around the tooth.”.
- gingivitis which means “inflammation around the tooth.”.
- gingivitis which means “inflammation around the tooth.”.
- a fourth aspect of the invention is an antibody raised against a polypeptide of the first aspect of the present invention.
- the antibody is specifically directed against the polypeptides of the present invention.
- antibody is used in the broadest sense and specifically covers monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), chimeric antibodies, diabodies, triabodies and antibody fragments.
- the antibodies of the present invention are preferably able to specifically bind to an antigenic polypeptide as hereinbefore described without cross-reacting with antigens of other polypeptides.
- binding specifically to is intended to refer to the binding of an antigen by an immunoglobulin variable region of an antibody with a dissociation constant (Kd) of 1 ⁇ M or lower as measured by surface plasmon resonance analysis using, for example a BIAcoreTM surface plasmon resonance system and BIAcoreTM kinetic evaluation software (eg. version 2.1).
- Kd dissociation constant
- the affinity or dissociation constant (Kd) for a specific binding interaction is preferably about 500 nM to about 50 pM, more preferably about 500 nM or lower, more preferably about 300 nM or lower and preferably at least about 300 nM to about 50 pM, about 200 nM to about 50 pM, and more preferably at least about 100 nM to about 50 pM, about 75 nM to about 50 pM, about 10 nM to about 50 pM.
- binding fragments of an antibody include (i) a Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CH1 domains; (ii) a F(ab′)2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment consisting of the VH and CH1 domains; (iv) a Fv fragment consisting of the VL and VH domains of a single arm of an antibody; (v) a dAb fragment which consists of a VH domain, or a VL domain; and (vi) an isolated complementarity determining region (CDR).
- a Fab fragment a monovalent fragment consisting of the VL, VH, CL and CH1 domains
- a F(ab′)2 fragment a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region
- a Fd fragment consisting of the VH and CH1 domain
- the two domains of the Fv fragment, VL and VH are coded by separate genes, they can be joined, using recombinant methods, by a synthetic linker that enables them to be made as a single protein chain in which the VL, and VH regions pair to form monovalent molecules (known as single chain Fv (scFv).
- scFv single chain Fv
- Other forms of single chain antibodies, such as diabodies or triabodies are also encompassed.
- Diabodies are bivalent, bispecific antibodies in which VH and VL domains are expressed on a single polypeptide chain, but using a linker that is too short to allow for pairing between the two domains on the same chain, thereby forcing the domains to pair with complementary domains of another chain and creating two antigen binding sites.
- Antibodies and antibody fragments may be produced in large amounts by standard techniques (eg in either tissue culture or serum free using a fermenter) and purified using affinity columns such as protein A (e.g. for murine Mabs), Protein G (eg for rat Mabs) or MEP HYPERCEL (eg for IgM and IgG Mabs).
- protein A e.g. for murine Mabs
- Protein G e.g for rat Mabs
- MEP HYPERCEL eg for IgM and IgG Mabs.
- Humanized antibodies may be prepared according to procedures in the literature (29,30) , The recently described “gene conversion metagenesis” strategy for the production of humanized monoclonal antibody may also be employed in the production of humanized antibodies (31) .
- techniques for generating the recombinant phase library of random combinations of heavy and light regions may be used to prepare recombinant antibodies (32) .
- the present invention also provides a composition useful in the prevention or treatment of periodontal disease, the composition comprising an antagonist of a P. gingivalis polypeptide of the first aspect of the present invention and a pharmaceutically acceptable carrier, wherein the antagonist inhibits P. gingivalis infection.
- the term “antagonist” refers to a nucleic acid, peptide, antibody, ligands or other chemical entity which inhibits the biological activity of the polypeptide of interest.
- a person skilled in the art would be familiar with techniques of testing and selecting suitable antagonists of a specific protein, such techniques would including binding assays.
- Possible antagonists of PG0350, PG1374, PG1019 and PG0618 are preferably antibodies, either monoclonal or polyclonal, which will inhibit the binding of these proteins to host cells or other substrates or they may be proteins or peptides that interfere with the binding of these proteins.
- the antibodies and antagonists of the present invention have a number of applications, for example, they can be used as antimicrobial preservatives, in oral care products (toothpastes and mouth rinses) for the control of dental plaque and suppression of pathogens associated with dental caries and periodontal diseases.
- the antibodies and antagonists of the present invention may also be used in pharmaceutical preparations (eg, topical and systemic anti infective medicines).
- a method of identifying a P. gingivalis polypeptide involved in the progression of periodontal disease comprising the steps of:
- step a) determining the relative amount of a polypeptide or peptide thereof produced by P. gingivalis grown under haem limited conditions; and b) determining the relative amount of the polypeptide or peptide thereof produced by P. gingivalis grown under higher haem conditions than step a); wherein an increase in the amount of the polypeptide or peptide fragment thereof detected in step a) compared to step b) indicates that the polypeptide is involved in the progression of periodontal disease.
- the concentration of haemin is about 0.1 ⁇ g/ml to about 0.5 ⁇ g/ml.
- Haem limiting conditions are achieved when the cell density of the P. gingivalis cells is significantly lower than that observed under the growth conditions of step (h) of the method of the invention.
- the higher haem conditions of step (b) is preferably achieved using a concentration of haemin of above 5 mg/ml.
- a comparison of the relative amounts of a polypeptide in the haem limited and higher haem conditions can be preferably determined by using a differential proteomic approach.
- the amount of a polypeptide is determined by qualitative proteomic analysis commonly used in the art, such as but not limited to, a combined strategy of in-solution and in-gel digestion and LC-MS/MS, analysis using stable isotope labelling strategies (ICAT) in combination with MS.
- ICAT stable isotope labelling strategies
- the isolated antigenic P. gingivalis polypeptides identified according to the method defined in the sixth aspect of the invention can be used as targets for treating and preventing periodontal disease.
- the isolated polypeptides can be used to develop vaccine compositions against P. gingivalis , for instance P. gingivalis infection, such as periodontal disease.
- the present invention also provides interfering RNA molecules which are targeted against the mRNA molecules encoding the polypeptides of the first aspect of the present invention. Accordingly, in a seventh aspect of the present invention there is provided an interfering RNA molecule, the molecule comprising a double stranded region of at least 19 base pairs in each strand wherein one of the strands of the double stranded region is complementary to a region of SEQ ID NO: 5 or SEQ ID NO: 6 or SEQ ID NO: 7 or SEQ ID NO: 8.
- RNA interference So called RNA interference or RNAi is well known and further information regarding RNAi is provided in Hannon (2002) Nature 418: 244-251, and McManus & Sharp (2002) Nature Reviews; Genetics 3(10): 737-747, the disclosures of which are incorporated herein by reference.
- the present invention also contemplates chemical modification(s) of siRNAs that enhance siRNA stability and support their use in vivo (see for example, Shen et al. (2006) Gene Therapy 13: 225-234). These modifications might include inverted abasic moieties at the 5′ and 3′ end of the sense strand oligonucleotide, and a single phosphorthioate linkage between the last two nucleotides at the 3′ end of the antisense strand.
- the double stranded region of the interfering RNA comprises at least 20, preferably at least 25, and most preferably at least 30 base pairs in each strand of the double stranded region.
- the present invention also provides a method of treating a subject for periodontal disease comprising administering to the subject at least one of the interfering RNA Molecules of the invention.
- P. gingivalis W50 (ATCC 53978) was obtained from the culture collection of the Centre for Oral Health Science, The University of Melbourne. Chemicals used were ultra high purity except for MS work where LC MS grade reagents were used (Sigma, Reidel-de Ha ⁇ umlaut over (c) ⁇ n).
- P. gingivalis W50 was grown in continuous culture using a Bioflo 110 fermenter/bioreactor (New Brunswick Scientific) with a 400 mL working volume.
- the growth medium was 37 g/mL brain heart infusion medium (Oxoid) supplemented with 5 mg/mL filler sterilized cysteine hydrochloride, 5.0 ⁇ g/mL haemin (haem-excess) or 0.1 ⁇ g/mL haemin (haem-limited). Growth was initiated by inoculating the culture vessel with a 24 h batch culture (100 mL) of P. gingivalis grown in the same medium (haem-excess).
- the medium reservoir pump was turned on and the medium flow adjusted to give a dilution rate of 0.1 h ⁇ 1 (mean generation time (MGT) of 6.9 h).
- MCT mean generation time
- the temperature of the vessel was maintained at 37° C. and the pH at 7.4 ⁇ 0.1.
- the culture was continuously gassed with 5% CO 2 in 95% N 2 .
- Cells were harvested during steady state growth, washed three times with wash buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 5 mM MgCl 2 ) at 5000 g for 30 min and disrupted with 3 passes through a French Pressure Cell (SLM, AMINCO) at 138 MPa.
- SLM, AMINCO French Pressure Cell
- the lysed cells were then centrifuged at 2000 g for 30 min to remove unbroken cells followed by ultracentrifugation at 100000 g, producing a soluble (supernatant) and membrane fraction. All fractions were carried out on
- Non-quantitative proteome analysis was carried out using two methods, in-solution digestion with trypsin followed by LCMS with gas phase fractionation (GPF) and in-gel digestion followed by LCMS (geLC-MS) as part of a combined strategy ( FIG. 1 ).
- in-solution digestion method protein was boiled at 95° C. for 3 min, precipitated with TCA (16%) and resuspended in solubilization buffer (8 M Urea, 50 mM Tris-HCl pH 8.3, 5 mM EDTA, 0.05% SDS). Protein concentration was determined with a BCA, protein reagent (Pierce) and adjusted to 2 ⁇ g/ ⁇ L.
- Reduction was carried out with 1 in M DTT for 30 min and alkylation using 10 mM iodoacetamide for 60 min.
- the solution was diluted with water to a final concentration of 1 M urea before digestion.
- Digestion was carried out using sequencing-grade modified trypsin (Promega) at a ratio of 1:100 w/w trypsin to protein at 37° C. for 16 h. The digestion was terminated by formic acid addition to a final concentration of 1% v/v.
- Peptides were then desalted using Sep-Pak C18 cartridges (Waters), dried using a vacuum centrifuge (Thermosavant) and resuspended in 5% acetonitrile in 0.1% TFA. An amount of peptide equivalent to 2 ⁇ g was injected for each LC-MS/MS analysis.
- the reduction solution was then replaced with 55 mM of iodoacetamide in 25 mM ABC and incubated for 45 min.
- the gel cubes were washed twice in 50 mM ABC and dehydrated with 100% ethanol.
- Thirty ⁇ L of modified sequencing-grade trypsin at a concentration of 5 ⁇ g/mL in 25 mM ABC buffer and 1 mM CaCl 2 was added and incubated at 4° C. for 30 min. Excess trypsin solution was removed and 15 ⁇ L of 25 mM ABC buffer was added. Digestion was carried out overnight at 37° C. and terminated by TFA addition to a final concentration of 0.1% v/v. The supernatant was then transferred to an eppendorf tube.
- Protein labelling and separation were based on the geLC-MS/MS approach (33) using the cleavable ICAT reagent (Applied Biosystems). Protein was first precipitated using TCA (16%) and solubilised with 6 M urea, 5 mM EDTA, 0.05% SDS and 50 mM Tris-HCl pH 8.3. Protein concentration was determined using the BCA protein reagent and adjusted to 1 mg/ml. 100 ⁇ g of protein from each growth condition was individually reduced using 2 ⁇ L of 50 mM Tris(2-carboxy-ethyl)phosphine hydrochloride for 1 h at 37° C.
- Reduced protein from the haem-limitation growth condition was then alkylated with the ICAT heavy reagent and protein from haem-excess growth condition with the ICAT light reagent.
- the two samples were then combined and subjected to SDS-PAGE on a precast Novex 10% NUPAGE gel (Invitrogen).
- the gel was stained for 5 min using SimplyBlueTM SafeStain (Invitrogen) followed by destaining with water.
- the gel lane was then excised into 20 sections from the top of the gel to the dye front.
- the excised sections were further diced into 1 mm 3 cubes and in-gel digested overnight and extracted twice according to the above procedure.
- the pooled supernatant was dried under reduced vacuum to about 50 ⁇ L followed by mixing with 500 ⁇ L, of affinity load buffer before loading onto the affinity column as per manufacturer's instruction (Applied Biosystems).
- Eluted peptides were dried and the biotin tag cleaved with neat TFA at 37° C. for 2 h. followed by drying under reduced vacuum.
- the dried samples were suspended in 35 ⁇ L of 5% acetonitrile in 0.1% TFA.
- MS was carried Out using an Esquire HCT ion trap mass spectrometer (Bruker Daltonics) coupled to an UltiMate Nano LC system (LC Packings—Dionex). Separation was achieved using a LC Packings reversed phase column (C18 PepMap100, 75 ⁇ m i.d. ⁇ 15 cm, 3 ⁇ m, 100 ⁇ ), and chilled in 0.1% formic acid with the following acetonitrile gradient: 0-5 min (0%), 5-10 min (0-10%), 10-100 min (10-50%), 100-120 min (50-80%), 120-130 min (80-100%).
- the LC output was directly interfaced to the nanospray ion source.
- MS acquisitions were performed under an ion charge control of 100000 in the m/z range of 300-1500 with maximum accumulation time of 100 ms.
- GPF three additional m/z ranges (300-800, 700-1200 and 1100-1500) were used to select for precursor ions and each m/z range was carried out in duplicate to increase the number of peptides identified.
- MS/MS acquisition was obtained over a mass range from 100-3000 m/z and was performed on up to 10 precursors for initial complete proteome analysis and 3 for ICAT analysis for the most intense multiply charged ions with an active exclusion time of 2 rain.
- Peak lists were generated using DataAnalysis 3.2 (Bruker Daltonics) using the Apex peak finder algorithm with a compound detection threshold of 10000 and signal to noise threshold of 5. A global charge limitation of +2 and +3 were set for exported data. Protein identification was achieved using the MASCOT search engine (MASCOT 2.1.02, Matrix Science) on MS/MS data queried against the P. gingivalis database obtained from The Institute for Genomic Research (TIGR) website (www.tigr.org).
- peptides with a probability based Mowse score corresponding to a p-value of at most 0.05 were regarded as positively identified, where the score is ⁇ log ⁇ 10(log(P)) and P is the probability that the observed match is a random event ii) where only one peptide was used in the identification of a specific protein and the MASCOT score was below 30, manual verification of the spectra was performed.
- the ratio of isotopically heavy 13 C to light 12 C ICAT labelled peptides was determined using a script from DataAnalysis (Bruker Daltonics) and verified manually based on measurement of the monoisotopic peak intensity (signal intensity and peak area) in a single MS spectrum.
- the minimum ion count of parent ions used for quantification was 2000 although >96% of both heavy and light precursor ions were >10000.
- gingivalis from genebank (ftp ://ftp.ncbi.nih.gov/genbank/genomes/Bacteria/Porphyromonas_gingivalis_W83/) using the program INteractive Codon Analysis 1.12a (http://www.bioinfo-hr.org/inca, (14) with ribosomal proteins and tRNA synthases being defined as highly expressed genes. Operon prediction was carried out from the Microbesonline website (http://microbesonline.org (36) .
- P. gingivalis W50 Open Reading Frame PG1374 potentially encodes an immunoreactive 47 KDa antigen (PG97) based on the P. gingivalis W83 genome (www.tigr.org).
- PG97 immunoreactive 47 KDa antigen
- PG1374 mutant a 672 bp upstream fragment of the PG1374 gene with flanking ApaI and AatII restriction sites (underlined) was generated from the W50 genomic DNA by PCR with primers ECR312ApaI-For (5′-AGA GGGCCC TAGCAATCATTGCATTGCT-3′) and ECR312AatII-Rev (5′-TGC GACGTC GTGTTACCAATAGAGGATT-3′).
- This fragment was cloned into AatII and BamHI sites on pAL30, pGem®T-easy (Promega) containing a subcloned ermF cassette (37) to create pAL36.
- a 565 bp fragment downstream of PG1374 with flanking PstI and NdeI restrictions sites was amplified with ECR312PstI-For2 (5′-TGA CTGCAG GCTTTCGACCTTGGATCTT-3′) and ECR312NdeI-Rev2 (5′-TCG CATATG AAGAAATAAGTGCCGTCGG-3′) primers, and cloned into PstI and NdeI restrictions sites in pAL36.
- the resulting plasmid having ermF cassette flanked with upstream and downstream fragments of the PG1374 open reading frame (designated as pAL36.1) was linearized with Scar and transformed into P. gingivalis W50 as previously described (38) .
- Transformed cells were selected after 7 days of incubation at 37° C. under anaerobic conditions on HBA plate containing 10 ⁇ g mL ⁇ 1 erythromycin. Confirmation of DNA integration was performed by PCR analysis and the resulting mutant was designated as ECR312.
- an antibiotic protection assay was carried out as described previously in a 24-well cell culture plate (39) . Briefly, a fixed number of P. gingivalis cells were allowed to invade a KB monolayer ( ⁇ 10 5 cells in each well). Non invaded or adhered cells were killed by further incubation for 1 h with gentamicin (300 ⁇ g/mL) and metronidazole (200 ⁇ g/mL). Colony forming units of invaded bacteria were then enumerated on horse blood agar plates.
- the cell binding assay was carried out as described previously (40) . Briefly, P. gingivalis was first grown to mid log phase to a cell density of ⁇ 2.9 ⁇ 10 9 cells/mL. The cells were then washed followed by labelling with 500 ⁇ g of fluorescein isothiocyanate (FITC) (Invitrogen) resuspended in 500 ⁇ L DMSO followed by incubation at 37° C. for 45 min with shaking. After incubation, the cells were further washed, resuspended in incomplete Earl's minimum essential medium (JRH Biosciences) and the P.
- FITC fluorescein isothiocyanate
- gingivalis cells adjusted based on cell counts using a FACSCaliber flow cytometer (Becton Dickinson, San Jose, Calif.). The green emission of FITC was measured with a 525-nm filter (FL1). The multiparametric data were analyzed using CellQuest software (Becton Dickinson, San Jose, Calif.). All measurements were done in duplicate, and for quantitation of FITC fluorescence, mean fluorescence intensity (MFI) values were used.
- FACSCaliber flow cytometer Becton Dickinson, San Jose, Calif.
- Binding of the wild type P. gingivalis and ECR312 was carried out in parallel by inoculating 200 ⁇ L of cell suspension onto the KB cells at 5% CO 2 atmosphere at 37° C. for 40 min. Following incubation the supernatant containing the KB cells and bacteria were transferred to a 1.5 mL tube. The remaining bound cells were then detached off the well with 200 ⁇ L of Trypsin-EDTA mixture (JRH Bioscience) for 5 min at 37° C. and pooled with the corresponding collected supernatants. 500 ⁇ L of complete EMEM was then added to inactivate the trypsin followed by three washes and final suspension in 1 mL PBS. The bound cells were counted on the flow cytometer as described earlier.
- proteome of P. gingivalis grown under haem-limitation was extensively analysed by two different approaches. Using in-solution digestion followed by LCMS with gas phase fractionation, 344 proteins were identified. In the geLCMS approach, 385 proteins were identified while 247 proteins were found by both approaches. With the combined strategy a total of 478 proteins were identified (see Table 1) with an estimated false positive rate of 0.4% calculated from searches against the P. gingivalis reverse database. 77.0% of all proteins were identified by ⁇ 2 unique peptides or by ⁇ 2 identical peptides from independent LCMS runs (from different m/z ranges or SDS PAGE bands).
- the 478 identified proteins represent ⁇ 25% of all the 1988 assigned protein-encoding genes identified by whole-genome analysis (43) . Although a quarter of the total predicted proteome was identified this figure is higher if the actual number of genes expressed during any one growth condition is taken into account. In Pseudomonas aeruginosa and Bacillus subtilis the percentage of total ORFs transcribed during a single growth condition was estimated to be 60% and 40%, respectively (44,45) . By examining the duty cycle limitation of their mass spectrometers Zhang and co-workers (46) estimated that around 60% of P. gingivalis predicted ORFs were expressed under their growth condition. Therefore based on these figures between 41-62% of P. gingivalis proteins expressed under the present growth conditions have been identified. The functional classification of the 478 identified proteins is shown in Table 1.
- TMHMM Transmembrane Hidden Markov Model
- CAD Codon Adaptation Index
- the functional classes of proteins with the highest percentage of identified proteins are those involved in energy metabolism (Table 1), typically those involved in fermentation (95%, CAI 0.70-0.80), glycolysis (82%, CAI 0.71-0.83) and metabolism of amino acids and amines (81%, CAI 0.71-0.84). This was largely expected as essential proteins involved in basic metabolic functions such as energy metabolism have been shown to be very abundant in the bacterial cell. Most importantly almost 90% of these proteins are predicted to be in the cytoplasm, which also made detection easier compared with membrane proteins.
- the functional classes of proteins represented least are those involved in transpositioning, hypothetical proteins and regulatory functions.
- P. gingivalis is known to be asaccharolytic (3) although the genome contains putative ORFs for all enzymes of the glycolytic pathway (43) .
- the poor utilization of this pathway has been attributed to the glucose kinase gene being interrupted by an insertion element (43) .
- glucose kinase or another glycolysis-specific enzyme, phosphofructokinase was not identified.
- all enzymes involved in gluconeogenesis were found, suggesting glucose necessary for processes such as polysaccharide biosynthesis may be derived via this pathway.
- the geLCMS approach was chosen, as the in-solution ICAT method was unsatisfactory due to the presence of strong interfering triply charged ions. The presence of these triply charged ions resulted in very low number of protein identifications.
- the ICAT labelled soluble and insoluble protein fractions were therefore independently separated by SDS-PACE and each gel lane divided into 20 sections for in-get tryptic digestion followed by affinity purification and LCMS. In total 142 proteins were identified. No matches to the reverse database were obtained indicating a low level of false positive identification.
- PG1374 and PG0350 belong to a new class of cysteine containing protein with leucine rich repeat domains similar to the L. monocytogenes internalin protein. In1J (52) .
- L. monocytogenes there are at least fifteen members of the internalin family and all have been found to share certain structural features consisting of a signal peptide, N-terminal leucine rich repeat domain followed by a conserved inter-repeat region. Many of these proteins are involved in the cellular invasion process (53) . It has not been demonstrated why multiple internalins exist, but they are proposed to confer tropism toward different cell types (54) .
- PG1374 and PG0350 both possesses a signal peptide and are part of the novel class of up to 34 cell surface-located outer membrane proteins that have no significant sequence similarities apart from a conserved C-Terminal Domain (CTD) of approximately 80 residues (56) .
- CCD conserved C-Terminal Domain
- PG1374 is strongly immunogenic when probed with sera from human periodontitis patients (57) which further suggests it to be involved in cell surface protein interactions.
- PG1019 was observed to be 25 times more abundant when the bacterium was grown under haem-limitation. Bioinformatic analyses suggest that PG1019 is a lipoprotein that is encoded by a gene located immediately upstream of a gene encoding a putative outer membrane receptor protein (PG1020) in a predicted operon. Multiple alignment (not shown) of PG1020 with known P.
- TonB-linked outer membrane receptors shows the presence of a putative TonB box (residues 118-126), that is one of the characteristics of TonB-linked receptors (67) and a conserved region (residues 236-272) which Simpson and co-workers (68) refer to as the TonB box IV region.
- TonB-linked outer membrane receptors have been implicated with many iron, iron complex and other micronutrient uptake systems. The high abundance of PG1019 under haem limited growth conditions would be consistent with this protein being an accessory lipoprotein to a Ton-B linked system involved in the transport of iron/iron complexes into the cell or the sensing of environmental iron or iron complexes, although this remains to be demonstrated.
- P. gingivalis FB1 a transcriptomic analysis using custom made P. gingivalis DNA microarrays of P. gingivalis W50 compared to a mutant lacking a function feoB1 gene ( P. gingivalis FB1) was performed.
- the wild type W50 and FB1 mutant were both grown in continuous culture in haem excess conditions.
- P. gingivalis FB1 has approximately half the cellular iron content of the wild type W50 (69) . Genes that show an increase in transcription are therefore likely to be upregulated in response to the decrease in intracellular or environmental iron content.
- Both PG1019 and PG1020 were significantly upregulated to similar levels in the FB1 mutant compared to the wild type.
- PG1019 showed a Log 2 increase of 2.46 and PG1020 showed a Log 2 increase of 2.33 at a significance level of P ⁇ 0.05 in biological replicates, this is further evidence that these genes are located in an operon. Further a separate transcriptomic DNA microarray analysis of P. gingivalis W50 indicated that there was little or no expression of the PG1019 gene during haem-excess growth.
- OxyR an oxygen sensitive transcriptional activator also plays a role in the expression of alkyl hydroperoxide during anaerobic growth (71) where a P. gingivalis OxyR ⁇ mutant shows decrease of 16 fold in gene expression. More recently Duran-Pinedo and co-workers also demonstrated the positive regulation of aphC expression by the RprY response regulator.
Abstract
Description
- The present invention relates to compositions and methods of isolating Porphyromonas gingivalis (P. gingivalis) proteins useful in the prevention of and treatment of periodontal disease. More particularly, the invention is directed to vaccine compositions and methods based on P. gingivalis proteins identified to be regulated by haem availability that can be used in the prevention and treatment of periodontal disease.
- Periodontal disease is a chronic bacterial infection that affects the gums and bone supporting the teeth. Periodontal disease begins when the bacteria in plaque (the sticky biofilm that constantly forms on teeth) causes the gums to become inflamed. Periodontal disease can affect the gingival tissue (gums); periodontal membrane (connective tissue embedded in the cementum and alveolar bone); cementum (mineralized connective tissue covering the roots of the teeth); and the alveolar bone (bone socket), Depending on the progression of the disease, there may occur a destruction of periodontal membranes, alveolar bone loss, and apical migration of the connective tissue attachment. Advanced periodontal disease may result in the formation of periodontal pockets harbouring bacterial plaque, and progressive loosening and eventual loss of teeth. Periodontal disease includes gingivitis that can advance to periodontitis. Chronic periodontitis is an inflammatory disease of the supporting tissues of teeth that is associated with specific bacteria in subgingival dental plaque. The disease has been estimated to affect around 35% of dentate adults and is a major cause of tooth loss in the Western world(1) . P. gingivalis, a member of the normal oral microflora of subgingival dental plague, has been implicated as one of the major opportunistic pathogens in the progression of this disease(2).
- P. gingivalis is a black-pigmented, asaccharolytic, Gram-negative anaerobic, cocco-bacillus, that relies on the fermentation of amino acids for energy production(3). Like most bacteria, P. gingivalis has an essential growth requirement for iron that it preferentially acquires in the form of haem, a molecule comprised of a protoporphyrin IX ring (PPIX) with a co-ordinated central ferrous atom(4). This utilization of haem as an iron source may reflect the inability of P. gingivalis to synthesize PPIX de novo(5). Haem is preferentially obtained from haemoglobin, and is acquired through the activity of the cell-surface Arg- and Lys-specific proteinase/adhesin complex(4,6,7), possibly in conjunction with a TonB-linked outer membrane receptor, HmuR(8). Unlike aerobic or facultative bacteria that obtain iron using siderophores P. gingivalis does not produce siderophores and lacks the ferric reductase activity usually associated with siderophore-mediated iron acquisition(9,10) . P. gingivalis stores haem on its surface in the form of μ-oxo bis-haem, which has inherent catalase activity that helps to protect the cell from oxidative attack(11). For P. gingivalis to be able to compete with the large numbers and diversity of bacteria within the micronutrient-limiting environment of the oral cavity(12) it not only has to establish itself but also has to evade or overcome numerous host defenses.
- The initiation and progression of periodontal disease is associated with bleeding at the site of disease, thereby providing an elevated level of haemoglobin. Therefore in order to help understand the mechanism by which P. gingivalis establishes and proliferates in subgingival plaque and initiates disease it is important to determine the changes in relative protein abundances of P. gingivalis during the transition from micronutrient poor (haem-limitation) to rich (haem-excess) conditions.
- Although many proteins have been associated with growth under haem-limitation(9,13), no extensive work on the P. gingivalis proteome or the changes to the proteome during haem-limitation has been reported.
- In developing compositions which would be useful in the prevention and treatment of periodontal disease it is desirable to identify agents that interfere and prevent the initial stages of the disease process.
- The present inventors have now developed methods for identifying specific P. gingivalis proteins regulated by haem availability that can be used as suitable targets for the prevention and treatment of periodontal disease.
- The present inventors have successfully developed methods of identifying P. gingivalis proteins regulated by haem availability that are responsible for P. gingivalis metabolism, virulence and invasion of host cells. In particular, two specific internalin-like P. gingivalis proteins, namely PG0350, PG1374 involved in the internalization of P. gingivalis by host cells, a hypothetical protein, PG1019 purported to be a cell surface lipoprotein and an alkyl hydroperoxide reductase protein, PG0618 have been identified as useful targets for the prevention and treatment of periodontal disease.
- A first aspect of the invention is an isolated antigenic P. gingivalis polypeptide, the polypeptide being selected from the group consisting of:
-
- (i) the PG0350 protein having the amino acid sequence of SEQ ID NO:1;
- (ii) the PG1374 protein having the amino acid sequence of SEQ ID NO:2;
- (iii) the PG1019 protein having the amino acid sequence of SEQ ID NO:3;
- (iv) the PG0618 protein having the amino acid sequence of SEQ ID NO:4;
- (v) an amino acid sequence at least 85% identical to the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:2 or SEQ ID NO:3 or SEQ ID NO:4; or
- (vi) an amino acid sequence comprising at least 10 amino acids identical to a contiguous amino acid sequence of SEQ ID NO:1 or SEQ ID NO:2 or SEQ ID NO:3 or SEQ ID NO:4.
- A second aspect of the invention is a vaccine composition for use in raising an immune response directed against P. gingivalis in a subject, the composition comprising an effective amount of at least one polypeptide of the first aspect of the invention and a pharmaceutically acceptable carrier.
- A third aspect of the invention is a method of preventing or treating a subject for periodontal disease comprising administering to the subject a vaccine composition according to the present invention.
- A fourth aspect of the invention is an antibody raised against a polypeptide of the first aspect of the present invention. Preferably, the antibody binds specifically to the polypeptides of the present invention.
- A fifth aspect of the invention is a composition useful in the prevention or treatment of periodontal disease, the composition comprising an antibody of the fourth aspect of the present invention and a pharmaceutically acceptable carrier.
- In a sixth aspect of the present invention there is provided a method of identifying a P. gingivalis polypeptide involved in the progression of periodontal disease, wherein the method comprises the steps of:
- a) determining the relative amount of a polypeptide or peptide thereof produced by P. gingivalis grown under haem limited conditions; and
b) determining the relative amount of the polypeptide or peptide thereof produced by P. gingivalis grown under higher haem conditions than step a);
wherein an increase in the amount of the polypeptide or peptide fragment thereof detected in step a) compared to step by indicates that the polypeptide is involved in the progression of periodontal disease. - In a seventh aspect of the present invention there is provided an interfering RNA molecule, the molecule comprising a double stranded region of at least 19 base pairs in each Strand wherein one of the strands of the double stranded region is complementary to a region of SEQ ID NO: 5 or SEQ ID NO: 6 or SEQ ID NO; 7 or SEQ ID NO: 8.
- In an eighth aspect of the present invention there is provided for the use of at least one polypeptide of the first aspect of the present invention in the manufacture of a medicament for the treatment of periodontal disease in a subject.
-
FIG. 1 shows a diagrammatic representation of the combined strategy used to identify proteins from P. gingivalis grown under haem-limitation. The lysed cells were prefractionated into soluble and insoluble fractions using ultra-centrifugation, followed by analysis of these two fractions. The separation and analysis procedure consists of two main methods; LCMS with gas phase fractionation and geLCMS. -
FIG. 2 shows a graph indicating the codon adaptation index (CAI) distribution of the identified P. gingivalis proteome and the predicted P. gingivalis genome calculated using INCA(14). Ribosomal and tRNA synthases were defined as highly expressed genes. Genes with less than 100 codons were excluded, bringing the total calculated genes to 1685. -
FIG. 3 shows the analysis and identification of PG0390 based on detection of a single peptide (A) Total ion chromatogram. (B) Mass spectrum at 54.8 min, insert showing an enlarged ICAT peptide ion pair at 703.9 and 708.4 m/z of ratio 1:2 (L/H). (C) Product ion spectrum for precursor 703.9 m/z. This peptide ion was identified as having the sequence LVDLNC*FDIK (MASCOT score=40; C* denotes ICAT modified cysteine). -
FIG. 4 shows the distribution of protein abundance based on ratio of haem-limitation over haem-excess (every one unit on theLog 2 scale indicates a two fold change). -
FIG. 5 shows binding to KB cells by P. gingivalis W50 (♦) and ECR312 (▪). The assay was carried out with two biological replication (n=6). Insert shows the gating of live KB cells based on forward and side scattering properties (top left), five peaks representing FITC fluorescence of hound P. gingivalis W50 to KB cells at P. gingivalis:KB cell ratios of 250 to 1250 (top right) and ECR312 (bottom right). -
FIG. 6 shows the amino acid sequence of PG0350 protein (referred to as SEQ ID NO:1 as also indicated in the sequence listing). -
FIG. 7 shows the amino acid sequence of PG1374 protein. (referred to as SEQ ID NO:2 as also indicated in the sequence listing). -
FIG. 8 shows the amino acid sequence of PG1019 protein (referred to as SEQ ID NO:3 as also indicated in the sequence listing). -
FIG. 9 shows the amino acid sequence of PG0618 protein (referred to as SEQ ID NO:4 as also indicated in the sequence listing). - The present invention advantageously provides the identification of P. gingivalis proteins regulated by haem availability as useful targets for the prevention and treatment of periodontal disease. Preferably, the invention provides the identification of P. gingivalis proteins upregulated by haem-limitation as useful targets for the prevention and treatment of periodontal disease.
- In particular, the invention provides an isolated antigenic P. gingivalis polypeptide, the polypeptide being selected from the group consisting of:
-
- (i) the PG0350 protein having the amino acid sequence of SEQ ID NO; 1;
- (ii) the PG1374 protein having the amino acid sequence of SEQ ID NO:2;
- (iii) the PG1019 protein having the amino acid sequence of SEQ ID NO:3;
- (iv) the PG0618 protein having the amino acid sequence of SEQ ID NO:4;
- (v) an amino acid sequence at least 85% identical to the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:2 or SEQ ID NO:3 or SEQ ID NO:4; or
- (vi) an amino acid sequence comprising at least 10 amino acids identical to a contiguous amino acid sequence of SEQ ID NO:1 or SEQ ID NO:2 or SEQ ID NO:3 or SEQ ID NO:4.
- Preferably, the isolated antigenic polypeptide is 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:2 or SEQ ID NO:3 or SEQ ID NO:4.
- Preferably, the isolated antigenic polypeptide comprises an amino acid sequence comprising at least 20, 30, 40, 50, 60, 70, 80, 90 or 100 amino acids identical to a contiguous amino acid sequence of SEQ ID NO:1 or SEQ ID NO:2 or SEQ ID NO:3 or SEQ ID NO:4.
- In a preferred embodiment, the antigenic polypeptides comprise amino acid sequences that compose the hydrophilic, surface-exposed regions of the PG1374 or PG0350 or PG1019 or PG0618 protein.
- The terms “peptides, proteins, and polypeptides” are used interchangeably herein. The polypeptides of the present invention can include recombinant polypeptides such as fusion polypeptides. Methods for the production of a fusion polypeptide are well-known to those skilled in the art.
- As will be well understood by those skilled in the art alterations may be made to the amino acid sequences set out in the Sequence Listings. These alterations may be deletions, insertions, or substitutions of amino acid residues. The altered polypeptides can be either naturally occurring (that is to say, purified or isolated from a natural source) or synthetic (for example, by site-directed metagenesis on the encoding DNA). It is intended that such altered polypeptides which have at least 85%, preferably at least 90%, 95%, 96%, 97%, 98% or 99% identity with the sequences set out in the Sequence Listing are within the scope of the present invention. Antibodies raised against these altered polypeptides will also bind to the polypeptides having one of the sequences set out in the Sequence Listings.
- Whilst the concept of conservative substitution is well understood by the person skilled in the art, for the sake of clarity conservative substitutions are those set out below.
-
Gly, Ala, Val, Ile, Leu, Met; Asp, Glu, Ser; Asn, Gln; Ser, Thr; Lys, Arg, His; Phe, Tyr, Trp, His; and Pro, Nα-alkalamino acids. - The practice of the invention will employ, unless otherwise indicated, conventional techniques of chemistry, molecular biology, microbiology, recombinant DNA, and immunology well known to those skilled in the art. Such techniques are described and explained throughout the literature in sources such as, Perbal, A Practical Guide to Molecular Cloning, John Wiley and Sons (1984)(15), Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbour Laboratory Press (1989)(16), Brown (editor), Essential Molecular Biology: A Practical Approach,
Volumes - An “isolated polypeptide” as used herein refers to a polypeptide that has been separated from other proteins, lipids, and nucleic acids with which it naturally occurs or the polypeptide or peptide may be synthetically synthesised. Preferably, the polypeptide is also separated from substances, for example, antibodies or gel matrix, for example, polyacrylamide, which are used to purify it. Preferably, the polypeptide constitutes at least 10%, 20%, 50%, 70%, and 80% of dry weight of the purified preparation. Preferably, the preparation contains a sufficient amount of polypeptide to allow for protein sequencing (i.e. at least 1, 10, or 100 mg).
- The isolated polypeptides described herein may be purified by standard techniques, such as column chromatography (using various matrices which interact with the protein products, such as ion exchange matrices, hydrophobic matrices and the like), affinity chromatography utilizing antibodies specific for the protein or other ligands which bind to the protein.
- An “antigenic polypeptide” used herein is a moiety, such as a polypeptide, analog or fragment thereof, that is capable of binding to a specific antibody with sufficiently high affinity to form a detectable antigen-antibody complex. Preferably, the antigenic polypeptide comprises an immunogenic component that is capable of eliciting a humoral and/or cellular immune response in a host animal.
- A “contiguous amino acid sequence” as used herein refers to a continuous stretch of amino acids.
- In determining whether or not two amino acid sequences fall within a specified percentage limit, those skilled in the art will be aware that it is necessary to conduct a side-by-side comparison or multiple alignments of sequences. In such comparisons or alignments, differences will arise in the positioning of non-identical residues, depending upon the algorithm used to perform the alignment. In the present context, reference to a percentage identity or similarity between two or more amino acid sequences shall be taken to refer to the number of identical and similar residues respectively, between said sequences as determined using any standard algorithm known to those skilled in the art. For example, amino acid sequence identities or similarities may be calculated using the GAP programme and/or aligned using the PILEUP programme of the Computer Genetics Group, Inc., University Research Park, Madison, Wis., United States of America(20). The GAP programme utilizes the algorithm of Needleman and Wunsch(21) to maximise the number of identical/similar residues and to minimise the number and length of sequence gaps in the alignment. Alternatively or in addition, wherein more than two amino acid sequences are being compared, the Clustal W programme(22) is used.
- The present invention also provides a vaccine composition for use in raising an immune response directed against P. gingivalis in a subject, the composition comprising an effective amount of at least one polypeptide of the first aspect of the invention and a pharmaceutically acceptable carrier.
- The vaccine composition of the present invention preferably comprises an antigenic polypeptide that comprises at least one antigen that can be used to confer immunity against P. gingivalis. The subject treated by the method of the invention may be selected from, but is not limited to, the group consisting of humans, sheep, cattle, horses, bovine, pigs, poultry, dogs and cats. Preferably, the subject is a human. An immune response directed against P. gingivalis is achieved in a subject, when the subject's immune system produces antibodies against the specific antigenic polypeptides.
- The vaccine composition is preferably administered to a subject to induce immunity to P. gingivalis and thereby prevent periodontal disease. The term “effective amount” as used herein means a dose sufficient to elicit an immune response against P. gingivalis. This will vary depending on the subject and the level of P. gingivalis infection and ultimately will be decided by the attending scientist, physician or veterinarian.
- The vaccine composition of the present invention comprises a suitable pharmaceutically-acceptable carrier, such as diluent and/or adjuvant suitable for administration to a human or animal subject. The vaccine preferably comprises a suitable adjuvant for delivery orally by nasal spray, or by injection to produce a specific immune response against P. gingivalis. A vaccine of the present invention can also be based upon a recombinant nucleic acid sequence encoding an antigenic polypeptide of the present invention, wherein the nucleic acid sequence is incorporated into an appropriate vector and expressed in a suitable transformed host (e.g. E. coli, Bacillus subtilis, Saccharomyces cerevisiae, COS cells, CHO cells and HeLa cells) containing the vector. The vaccine can be produced using recombinant DNA methods as illustrated herein, or can be synthesized chemically from the amino acid sequence described in the present invention. Additionally, according to the present invention, the antigenic polypeptides may be used to generate P. gingivalis antisera useful for passive immunization against periodontal disease and infections caused by P. gingivalis.
- Various adjuvants known those skilled in the art are commonly used in conjunction with vaccine formulations. The adjuvants aid by modulating the immune response and in attaining a more durable and higher level of immunity using smaller amounts of vaccine antigen or fewer doses than if the vaccine antigen were administered alone. Examples of adjuvants include incomplete Freunds adjuvant (IFA), Adjuvant 65 (containing peanut oil, mannide monooleate and aluminium monostrearate), oil emulsions, Ribi adjuvant, the pluronic polyols, polyamines, Avridine, Quil A, saponin, MPL, QS-21, and mineral gels such as aluminium salts. Other examples include oil in water emulsions such as SAF-1, SAF-0, MF59, Seppic ISA720, and other particulate adjuvants such as ISCOMs and ISCOM matrix. An extensive but exhaustive list of other examples of adjuvants are listed in Cox and Coulter 1992(23). In addition to the adjuvant the vaccine may include conventional pharmaceutically acceptable carriers, excipients, fillers, buffers or diluents as appropriate. One or more doses of the vaccine containing adjuvant may be administered prophylactically to prevent periodontal disease or therapeutically to treat already present periodontal disease.
- In another preferred vaccine composition the preparation is combined with a mucosal adjuvant and administered via the oral or nasal mute. Examples of mucosal adjuvants are cholera toxin and heat labile E. coli toxin, the non-toxic B sub-units of these toxins, genetic mutants of these toxins which have reduced toxicity. Other methods which may be utilised to deliver the antigenic polypeptides orally or nasally include incorporation of the polypeptides into particles of biodegradable polymers (such as acrylates or polyesters) by micro-encapsulation to aid uptake of the microspheres from the gastrointestinal tract or nasal cavity and to protect degradation of the proteins. Liposomes, ISCOMs, hydrogels are examples of other potential methods which may be further enhanced by the incorporation of targeting molecules such as LTB, CTB or lectins (mannan, chitin, and chitosan) for delivery of the antigenic polypeptides to the mucosal immune system. In addition to the vaccine and the mucosal adjuvant or delivery system the vaccine may include conventional pharmaceutically acceptable carriers, excipients, fillers, coatings, dispersion media, antibacterial and antifungal agents, buffers or diluents as appropriate.
- Another mode of this embodiment provides for either, a live recombinant viral vaccine, recombinant bacterial vaccine, recombinant attenuated bacterial vaccine, or an inactivated recombinant viral vaccine which is used to protect against infections caused by P. gingivalis. Vaccinia virus is the best known example, in the art, of an infectious virus that is engineered to express vaccine antigens derived from other organisms. The recombinant live vaccinia virus, which is attenuated or otherwise treated so that it does not caused disease by itself, is used to immunise the host. Subsequent replication of the recombinant virus within the host provides a continual stimulation of the immune system with the vaccine antigens such as the antigenic polypeptides, thereby providing long lasting immunity.
- Other live vaccine vectors include: adenovirus, cytomegalovirus, and preferably the poxviruses such as vaccinia(24) and attenuated salmonella strains(25-28). Live vaccines are particularly advantageous because they continually stimulate the immune system which can confer substantially long-lasting immunity. When the immune response is protective against subsequent P. gingivalis infection, the live vaccine itself may be used in a protective vaccine against P. gingivalis. In particular, the live vaccine can be based on a bacterium that is a commensal inhabitant of the oral cavity. This bacterium can be transformed with a vector carrying a recombinant inactivated polypeptide and then used to colonise the oral cavity, in particular the oral mucosa. Once colonised the oral mucosa, the expression of the recombinant protein will stimulate the mucosal associated lymphoid tissue to produce neutralising antibodies. For example, using molecular biological techniques the genes encoding the polypeptides may be inserted into the vaccinia virus genomic DNA at a site which allows for expression of epitopes but does not negatively affect the growth or replication of the vaccinia virus vector. The resultant recombinant virus can be used as the immunogen in a vaccine formulation. The same methods can be used to construct an inactivated recombinant viral vaccine formulation except the recombinant virus is inactivated, such as by chemical means known in the art, prior to use as an immunogen and without substantially affecting the immunogenicity of the expressed immunogen.
- As an alternative to active immunisation, immunisation may be passive, i.e. immunisation comprising administration of purified immunoglobulin containing an antibody against a polypeptide of the present invention.
- The antigenic polypeptides used in the methods and compositions of the present invention may be combined with suitable excipients, such as emulsifiers, surfactants, stabilisers, dyes, penetration enhancers, anti-oxidants, water, salt solutions, alcohols, polyethylene glycols, gelatine, lactose, magnesium sterate and silicic acid. The antigenic polypeptides are preferably formulated as a sterile aqueous solution. The vaccine compositions of the present invention may be used to complement existing treatments for periodontal disease.
- A third aspect of the invention is a method of preventing or treating a subject for periodontal disease comprising administering to the subject a vaccine composition according to the present invention.
- In the present method a subject is treated including prophylactic treatment for periodontal disease. Periodontal diseases range from simple gum inflammation to serious disease that results in major damage to the soft tissue and bone that support the teeth. Periodontal disease includes gingivitis and periodontitis. Bacteria, mainly Gram-negative species including P. gingivalis cause inflammation of the gums that is called “gingivitis.” In gingivitis, the gums become red, swollen and can bleed easily. When gingivitis is not treated, it can advance to “periodontitis” (which means “inflammation around the tooth.”). In periodontitis, gums pull away from the teeth and form “pockets” that are infected. The body's immune system tights the bacteria as the plaque spreads and grows below the gum line. If not treated, the bones, gums, and connective tissue that support the teeth are destroyed. The teeth may eventually become loose and have to be removed.
- A fourth aspect of the invention is an antibody raised against a polypeptide of the first aspect of the present invention. Preferably, the antibody is specifically directed against the polypeptides of the present invention.
- In the present specification the term “antibody” is used in the broadest sense and specifically covers monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), chimeric antibodies, diabodies, triabodies and antibody fragments. The antibodies of the present invention are preferably able to specifically bind to an antigenic polypeptide as hereinbefore described without cross-reacting with antigens of other polypeptides.
- The term “binds specifically to” as used herein, is intended to refer to the binding of an antigen by an immunoglobulin variable region of an antibody with a dissociation constant (Kd) of 1 μM or lower as measured by surface plasmon resonance analysis using, for example a BIAcore™ surface plasmon resonance system and BIAcore™ kinetic evaluation software (eg. version 2.1). The affinity or dissociation constant (Kd) for a specific binding interaction is preferably about 500 nM to about 50 pM, more preferably about 500 nM or lower, more preferably about 300 nM or lower and preferably at least about 300 nM to about 50 pM, about 200 nM to about 50 pM, and more preferably at least about 100 nM to about 50 pM, about 75 nM to about 50 pM, about 10 nM to about 50 pM.
- It has been shown that the antigen-binding function of an antibody can be performed by fragments of a full length antibody. Examples of binding fragments of an antibody include (i) a Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CH1 domains; (ii) a F(ab′)2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment consisting of the VH and CH1 domains; (iv) a Fv fragment consisting of the VL and VH domains of a single arm of an antibody; (v) a dAb fragment which consists of a VH domain, or a VL domain; and (vi) an isolated complementarity determining region (CDR). Furthermore, although the two domains of the Fv fragment, VL and VH, are coded by separate genes, they can be joined, using recombinant methods, by a synthetic linker that enables them to be made as a single protein chain in which the VL, and VH regions pair to form monovalent molecules (known as single chain Fv (scFv). Other forms of single chain antibodies, such as diabodies or triabodies are also encompassed. Diabodies are bivalent, bispecific antibodies in which VH and VL domains are expressed on a single polypeptide chain, but using a linker that is too short to allow for pairing between the two domains on the same chain, thereby forcing the domains to pair with complementary domains of another chain and creating two antigen binding sites.
- Various procedures known in the art may also be used for the production of the monoclonal and polyclonal antibodies as well as various recombinant and synthetic antibodies which can bind to the antigenic polypeptides of the present invention. In addition, those skilled in the art would be familiar with various adjuvants that can be used to increase the immunological response, depending on the host species, and include, but are not limited to, Freud's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, dinitrophenol, and potentially useful human adjuvants such as Bacillus Calmette-Guerin (BCG) and Corynebacterium parvum. Antibodies and antibody fragments may be produced in large amounts by standard techniques (eg in either tissue culture or serum free using a fermenter) and purified using affinity columns such as protein A (e.g. for murine Mabs), Protein G (eg for rat Mabs) or MEP HYPERCEL (eg for IgM and IgG Mabs).
- Recombinant human or humanized versions of monoclonal antibodies are a preferred embodiment for human therapeutic applications. Humanized antibodies may be prepared according to procedures in the literature(29,30), The recently described “gene conversion metagenesis” strategy for the production of humanized monoclonal antibody may also be employed in the production of humanized antibodies(31). Alternatively, techniques for generating the recombinant phase library of random combinations of heavy and light regions may be used to prepare recombinant antibodies(32).
- The present invention also provides a composition useful in the prevention or treatment of periodontal disease, the composition comprising an antagonist of a P. gingivalis polypeptide of the first aspect of the present invention and a pharmaceutically acceptable carrier, wherein the antagonist inhibits P. gingivalis infection.
- As used herein, the term “antagonist” refers to a nucleic acid, peptide, antibody, ligands or other chemical entity which inhibits the biological activity of the polypeptide of interest. A person skilled in the art would be familiar with techniques of testing and selecting suitable antagonists of a specific protein, such techniques would including binding assays. Possible antagonists of PG0350, PG1374, PG1019 and PG0618 are preferably antibodies, either monoclonal or polyclonal, which will inhibit the binding of these proteins to host cells or other substrates or they may be proteins or peptides that interfere with the binding of these proteins.
- The antibodies and antagonists of the present invention have a number of applications, for example, they can be used as antimicrobial preservatives, in oral care products (toothpastes and mouth rinses) for the control of dental plaque and suppression of pathogens associated with dental caries and periodontal diseases. The antibodies and antagonists of the present invention may also be used in pharmaceutical preparations (eg, topical and systemic anti infective medicines).
- In a sixth aspect of the present invention there is provided a method of identifying a P. gingivalis polypeptide involved in the progression of periodontal disease, wherein the method comprises the steps of:
- a) determining the relative amount of a polypeptide or peptide thereof produced by P. gingivalis grown under haem limited conditions; and
b) determining the relative amount of the polypeptide or peptide thereof produced by P. gingivalis grown under higher haem conditions than step a);
wherein an increase in the amount of the polypeptide or peptide fragment thereof detected in step a) compared to step b) indicates that the polypeptide is involved in the progression of periodontal disease. - In order to grow P. gingivalis under haem limited conditions, it is preferred that the concentration of haemin is about 0.1 μg/ml to about 0.5 μg/ml. Haem limiting conditions are achieved when the cell density of the P. gingivalis cells is significantly lower than that observed under the growth conditions of step (h) of the method of the invention. The higher haem conditions of step (b) is preferably achieved using a concentration of haemin of above 5 mg/ml.
- A comparison of the relative amounts of a polypeptide in the haem limited and higher haem conditions can be preferably determined by using a differential proteomic approach. Preferably, the amount of a polypeptide is determined by qualitative proteomic analysis commonly used in the art, such as but not limited to, a combined strategy of in-solution and in-gel digestion and LC-MS/MS, analysis using stable isotope labelling strategies (ICAT) in combination with MS.
- The isolated antigenic P. gingivalis polypeptides identified according to the method defined in the sixth aspect of the invention can be used as targets for treating and preventing periodontal disease. In particular, the isolated polypeptides can be used to develop vaccine compositions against P. gingivalis, for instance P. gingivalis infection, such as periodontal disease.
- The present invention also provides interfering RNA molecules which are targeted against the mRNA molecules encoding the polypeptides of the first aspect of the present invention. Accordingly, in a seventh aspect of the present invention there is provided an interfering RNA molecule, the molecule comprising a double stranded region of at least 19 base pairs in each strand wherein one of the strands of the double stranded region is complementary to a region of SEQ ID NO: 5 or SEQ ID NO: 6 or SEQ ID NO: 7 or SEQ ID NO: 8.
- So called RNA interference or RNAi is well known and further information regarding RNAi is provided in Hannon (2002) Nature 418: 244-251, and McManus & Sharp (2002) Nature Reviews; Genetics 3(10): 737-747, the disclosures of which are incorporated herein by reference.
- The present invention also contemplates chemical modification(s) of siRNAs that enhance siRNA stability and support their use in vivo (see for example, Shen et al. (2006) Gene Therapy 13: 225-234). These modifications might include inverted abasic moieties at the 5′ and 3′ end of the sense strand oligonucleotide, and a single phosphorthioate linkage between the last two nucleotides at the 3′ end of the antisense strand.
- It is preferred that the double stranded region of the interfering RNA comprises at least 20, preferably at least 25, and most preferably at least 30 base pairs in each strand of the double stranded region. The present invention also provides a method of treating a subject for periodontal disease comprising administering to the subject at least one of the interfering RNA Molecules of the invention.
- In order that the nature of the present invention may be more clearly understood preferred forms thereof will now be described with reference to the following example.
- P. gingivalis W50 (ATCC 53978) was obtained from the culture collection of the Centre for Oral Health Science, The University of Melbourne. Chemicals used were ultra high purity except for MS work where LC MS grade reagents were used (Sigma, Reidel-de Ha{umlaut over (c)}n).
- 1.2 Growth and Harvesting of P. gingivalis
- P. gingivalis W50 was grown in continuous culture using a
Bioflo 110 fermenter/bioreactor (New Brunswick Scientific) with a 400 mL working volume. The growth medium was 37 g/mL brain heart infusion medium (Oxoid) supplemented with 5 mg/mL filler sterilized cysteine hydrochloride, 5.0 μg/mL haemin (haem-excess) or 0.1 μg/mL haemin (haem-limited). Growth was initiated by inoculating the culture vessel with a 24 h batch culture (100 mL) of P. gingivalis grown in the same medium (haem-excess). After 24 h of batch culture growth, the medium reservoir pump was turned on and the medium flow adjusted to give a dilution rate of 0.1 h−1 (mean generation time (MGT) of 6.9 h). The temperature of the vessel was maintained at 37° C. and the pH at 7.4±0.1. The culture was continuously gassed with 5% CO2 in 95% N2. Cells were harvested during steady state growth, washed three times with wash buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 5 mM MgCl2) at 5000 g for 30 min and disrupted with 3 passes through a French Pressure Cell (SLM, AMINCO) at 138 MPa. The lysed cells were then centrifuged at 2000 g for 30 min to remove unbroken cells followed by ultracentrifugation at 100000 g, producing a soluble (supernatant) and membrane fraction. All fractions were carried out on ice. - Non-quantitative proteome analysis was carried out using two methods, in-solution digestion with trypsin followed by LCMS with gas phase fractionation (GPF) and in-gel digestion followed by LCMS (geLC-MS) as part of a combined strategy (
FIG. 1 ). For the in-solution digestion method, protein was boiled at 95° C. for 3 min, precipitated with TCA (16%) and resuspended in solubilization buffer (8 M Urea, 50 mM Tris-HCl pH 8.3, 5 mM EDTA, 0.05% SDS). Protein concentration was determined with a BCA, protein reagent (Pierce) and adjusted to 2 μg/μL. Reduction was carried out with 1 in M DTT for 30 min and alkylation using 10 mM iodoacetamide for 60 min. The solution was diluted with water to a final concentration of 1 M urea before digestion. Digestion was carried out using sequencing-grade modified trypsin (Promega) at a ratio of 1:100 w/w trypsin to protein at 37° C. for 16 h. The digestion was terminated by formic acid addition to a final concentration of 1% v/v. Peptides were then desalted using Sep-Pak C18 cartridges (Waters), dried using a vacuum centrifuge (Thermosavant) and resuspended in 5% acetonitrile in 0.1% TFA. An amount of peptide equivalent to 2 μg was injected for each LC-MS/MS analysis. - For the geLC-MS method, 25 μg of protein was separated on a precast Novex 12% Tris-HCl glycine gel (Invitrogen) and stained overnight with Commassie Brilliant Blue G-250 (Sigma). The gel was divided into thirty individual sections which were then excised and cut into approximately 1 mm3 cubes. Destaining was carried out three times with a solution of 50% ethanol and 25 mM ammonium bicarbonate (ABC) buffer followed by dehydration with 100% ethanol. Reduction was carried out by incubating the dehydrated gel cubes with 10 nM DTT in 25 mM ABC for 60 min at 56° C. The reduction solution was then replaced with 55 mM of iodoacetamide in 25 mM ABC and incubated for 45 min. The gel cubes were washed twice in 50 mM ABC and dehydrated with 100% ethanol. Thirty μL of modified sequencing-grade trypsin at a concentration of 5 μg/mL in 25 mM ABC buffer and 1 mM CaCl2 was added and incubated at 4° C. for 30 min. Excess trypsin solution was removed and 15 μL of 25 mM ABC buffer was added. Digestion was carried out overnight at 37° C. and terminated by TFA addition to a final concentration of 0.1% v/v. The supernatant was then transferred to an eppendorf tube. To the
gel pieces 50 μL, of 50% ethanol in 0.1% TFA was added and sonicated for 15 min. The process was repeated and all supernatants derived from one gel section were pooled and dried to about 10 μL using a vacuum centrifuge. - Protein labelling and separation were based on the geLC-MS/MS approach(33) using the cleavable ICAT reagent (Applied Biosystems). Protein was first precipitated using TCA (16%) and solubilised with 6 M urea, 5 mM EDTA, 0.05% SDS and 50 mM Tris-HCl pH 8.3. Protein concentration was determined using the BCA protein reagent and adjusted to 1 mg/ml. 100 μg of protein from each growth condition was individually reduced using 2 μL of 50 mM Tris(2-carboxy-ethyl)phosphine hydrochloride for 1 h at 37° C. Reduced protein from the haem-limitation growth condition was then alkylated with the ICATheavy reagent and protein from haem-excess growth condition with the ICATlight reagent. The two samples were then combined and subjected to SDS-PAGE on a
precast Novex 10% NUPAGE gel (Invitrogen). The gel was stained for 5 min using SimplyBlue™ SafeStain (Invitrogen) followed by destaining with water. The gel lane was then excised into 20 sections from the top of the gel to the dye front. - The excised sections were further diced into 1 mm3 cubes and in-gel digested overnight and extracted twice according to the above procedure. The pooled supernatant was dried under reduced vacuum to about 50 μL followed by mixing with 500 μL, of affinity load buffer before loading onto the affinity column as per manufacturer's instruction (Applied Biosystems). Eluted peptides were dried and the biotin tag cleaved with neat TFA at 37° C. for 2 h. followed by drying under reduced vacuum. The dried samples were suspended in 35 μL of 5% acetonitrile in 0.1% TFA.
- MS was carried Out using an Esquire HCT ion trap mass spectrometer (Bruker Daltonics) coupled to an UltiMate Nano LC system (LC Packings—Dionex). Separation was achieved using a LC Packings reversed phase column (C18 PepMap100, 75 μm i.d.×15 cm, 3 μm, 100 Å), and chilled in 0.1% formic acid with the following acetonitrile gradient: 0-5 min (0%), 5-10 min (0-10%), 10-100 min (10-50%), 100-120 min (50-80%), 120-130 min (80-100%).
- The LC output was directly interfaced to the nanospray ion source. MS acquisitions were performed under an ion charge control of 100000 in the m/z range of 300-1500 with maximum accumulation time of 100 ms. When using GPF three additional m/z ranges (300-800, 700-1200 and 1100-1500) were used to select for precursor ions and each m/z range was carried out in duplicate to increase the number of peptides identified. MS/MS acquisition was obtained over a mass range from 100-3000 m/z and was performed on up to 10 precursors for initial complete proteome analysis and 3 for ICAT analysis for the most intense multiply charged ions with an active exclusion time of 2 rain.
- Peak lists were generated using DataAnalysis 3.2 (Bruker Daltonics) using the Apex peak finder algorithm with a compound detection threshold of 10000 and signal to noise threshold of 5. A global charge limitation of +2 and +3 were set for exported data. Protein identification was achieved using the MASCOT search engine (MASCOT 2.1.02, Matrix Science) on MS/MS data queried against the P. gingivalis database obtained from The Institute for Genomic Research (TIGR) website (www.tigr.org). The matched peptides were further evaluated using the following criteria, i) peptides with a probability based Mowse score corresponding to a p-value of at most 0.05 were regarded as positively identified, where the score is −log×10(log(P)) and P is the probability that the observed match is a random event ii) where only one peptide was used in the identification of a specific protein and the MASCOT score was below 30, manual verification of the spectra was performed.
- To increase confidence in the identification of ICAT-labeled proteins especially for those with single peptide hits, additional filters were applied as follows: i) the heavy and light peptides of an ICAT pair must have exhibited closely eluting peaks as determined from their extracted ion chromatograms ii) for proteins with a single unique peptide, this peptide must have been identified more than once (e.g in different SDS-PAGE fractions or in both the light and heavy ICAT forms iii) if a single peptide did not meet the criteria of (ii), the MASCOT score must have been ≧25, the expectation value ≦0.01 and the MS/MS spectrum must have exhibited a contiguous series of ‘b’ or ‘y’-type ions with the intense ions being accounted.
- To independently estimate the level of false positive assignments, a reverse database of P. gingivalis was created by reversing the order of the amino acid sequences for each protein such that the database is identical in size to the normal database in terms of the protein number, size and distribution of amino acids(34). The false positive rate was thus estimated as NR/NF where NR=number of peptides identified with the reverse database (MASCOT score of peptide above threshold for the reverse database) and NF=number of peptides identified with the normal database (MASCOT score of peptide above threshold for normal database). False positives were determined from the comprehensive proteome analysis (NF=18375 peptides) and quantitative ICAT analysis (NF=530 peptides).
- The ratio of isotopically heavy 13C to light 12C ICAT labelled peptides was determined using a script from DataAnalysis (Bruker Daltonics) and verified manually based on measurement of the monoisotopic peak intensity (signal intensity and peak area) in a single MS spectrum. The minimum ion count of parent ions used for quantification was 2000 although >96% of both heavy and light precursor ions were >10000. In the case of poorly resolved spectra, the ratio was determined from the area of the reconstructed extracted ion chromatograms (EIC) of the parent ions. Averages were calculated for multiple peptides derived from a single parent protein and outliers were removed using the Grubb's test with α=0.05.
- The cellular localisation of P. gingivalis proteins was predicted using CELLO (http://cello.life.nctu.edu.tw(35) and transmembrane helices using TMHMM 2.0 (www.cbs.dtu.dk/services/TMHMM-2.0) based on the sequence obtained from TIGR. To estimate the relative expression level of the proteins identified as compared to the theoretical proteome CAI values were calculated based on the coding sequence of P. gingivalis from genebank (ftp ://ftp.ncbi.nih.gov/genbank/genomes/Bacteria/Porphyromonas_gingivalis_W83/) using the program INteractive Codon Analysis 1.12a (http://www.bioinfo-hr.org/inca,(14) with ribosomal proteins and tRNA synthases being defined as highly expressed genes. Operon prediction was carried out from the Microbesonline website (http://microbesonline.org(36).
- P. gingivalis W50 Open Reading Frame PG1374 potentially encodes an immunoreactive 47 KDa antigen (PG97) based on the P. gingivalis W83 genome (www.tigr.org). To construct P. gingivalis PG1374 mutant, a 672 bp upstream fragment of the PG1374 gene with flanking ApaI and AatII restriction sites (underlined) was generated from the W50 genomic DNA by PCR with primers ECR312ApaI-For (5′-AGAGGGCCCTAGCAATCATTGCATTGCT-3′) and ECR312AatII-Rev (5′-TGCGACGTCGTGTTACCAATAGAGGATT-3′). This fragment was cloned into AatII and BamHI sites on pAL30, pGem®T-easy (Promega) containing a subcloned ermF cassette(37) to create pAL36. Similarly, a 565 bp fragment downstream of PG1374 with flanking PstI and NdeI restrictions sites was amplified with ECR312PstI-For2 (5′-TGACTGCAGGCTTTCGACCTTGGATCTT-3′) and ECR312NdeI-Rev2 (5′-TCGCATATGAAGAAATAAGTGCCGTCGG-3′) primers, and cloned into PstI and NdeI restrictions sites in pAL36. The resulting plasmid having ermF cassette flanked with upstream and downstream fragments of the PG1374 open reading frame (designated as pAL36.1) was linearized with Scar and transformed into P. gingivalis W50 as previously described(38). Transformed cells were selected after 7 days of incubation at 37° C. under anaerobic conditions on HBA plate containing 10 μg mL−1 erythromycin. Confirmation of DNA integration was performed by PCR analysis and the resulting mutant was designated as ECR312.
- To compare the invasion efficiencies of W50 and ECR312, an antibiotic protection assay was carried out as described previously in a 24-well cell culture plate(39). Briefly, a fixed number of P. gingivalis cells were allowed to invade a KB monolayer (˜105 cells in each well). Non invaded or adhered cells were killed by further incubation for 1 h with gentamicin (300 μg/mL) and metronidazole (200 μg/mL). Colony forming units of invaded bacteria were then enumerated on horse blood agar plates.
- The cell binding assay was carried out as described previously(40). Briefly, P. gingivalis was first grown to mid log phase to a cell density of ˜2.9×109 cells/mL. The cells were then washed followed by labelling with 500 μg of fluorescein isothiocyanate (FITC) (Invitrogen) resuspended in 500 μL DMSO followed by incubation at 37° C. for 45 min with shaking. After incubation, the cells were further washed, resuspended in incomplete Earl's minimum essential medium (JRH Biosciences) and the P. gingivalis cells adjusted based on cell counts using a FACSCaliber flow cytometer (Becton Dickinson, San Jose, Calif.). The green emission of FITC was measured with a 525-nm filter (FL1). The multiparametric data were analyzed using CellQuest software (Becton Dickinson, San Jose, Calif.). All measurements were done in duplicate, and for quantitation of FITC fluorescence, mean fluorescence intensity (MFI) values were used.
- Binding of the wild type P. gingivalis and ECR312 was carried out in parallel by inoculating 200 μL of cell suspension onto the KB cells at 5% CO2 atmosphere at 37° C. for 40 min. Following incubation the supernatant containing the KB cells and bacteria were transferred to a 1.5 mL tube. The remaining bound cells were then detached off the well with 200 μL of Trypsin-EDTA mixture (JRH Bioscience) for 5 min at 37° C. and pooled with the corresponding collected supernatants. 500 μL of complete EMEM was then added to inactivate the trypsin followed by three washes and final suspension in 1 mL PBS. The bound cells were counted on the flow cytometer as described earlier.
- 2.1 Growth of P. gingivalis in Continuous Culture
- When grown in continuous culture in a rich medium containing excess haem P. gingivalis W50 achieved a steady state cell density approximately 48 h after inoculation of 2.03±0.04 mg cellular dry weight/mL. When the concentration of haemin in the growth medium was decreased from 5.0 μg/ml to 0.1 μg/ml, a significantly lower steady state cell density of 0.99±0.20 mg cellular dry weight/mL was achieved demonstrating that haem availability was limiting growth. The effect of haem-limitation on cell density was alleviated when haem was added back into the culture.
- The growth of P. gingivalis during haem-limitation was in agreement with previous studies using chemostats with a P. gingivalis mean generation time of 6.9 h(41,42). Due to the inability of P. gingivalis to synthesize PPIX, this essential nutrient is thought to be acquired through proteolysis of haemoglobin and other haem containing plasma proteins(9) and a deficiency in haem was thus reflected in the significantly lower cell density.
- 2.2 Proteome Analysis of P. gingivalis Grown Under Haem-Limitation
- The proteome of P. gingivalis grown under haem-limitation was extensively analysed by two different approaches. Using in-solution digestion followed by LCMS with gas phase fractionation, 344 proteins were identified. In the geLCMS approach, 385 proteins were identified while 247 proteins were found by both approaches. With the combined strategy a total of 478 proteins were identified (see Table 1) with an estimated false positive rate of 0.4% calculated from searches against the P. gingivalis reverse database. 77.0% of all proteins were identified by ≧2 unique peptides or by ≧2 identical peptides from independent LCMS runs (from different m/z ranges or SDS PAGE bands). The 478 identified proteins represent ˜25% of all the 1988 assigned protein-encoding genes identified by whole-genome analysis(43). Although a quarter of the total predicted proteome was identified this figure is higher if the actual number of genes expressed during any one growth condition is taken into account. In Pseudomonas aeruginosa and Bacillus subtilis the percentage of total ORFs transcribed during a single growth condition was estimated to be 60% and 40%, respectively(44,45). By examining the duty cycle limitation of their mass spectrometers Zhang and co-workers(46) estimated that around 60% of P. gingivalis predicted ORFs were expressed under their growth condition. Therefore based on these figures between 41-62% of P. gingivalis proteins expressed under the present growth conditions have been identified. The functional classification of the 478 identified proteins is shown in Table 1.
-
TABLE 1 Coverage of the theoretical proteome of P. gingivalis using the combined strategy shown in FIG. 1. Proteins ID/ % of Functional class of proteinsa Total Proteinb class ID Energy metabolism 78/140 55.7 Protein synthesis 68/117 58.1 Fatty acid and phospholipid metabolism 9/16 56.3 Protein fate 37/75 49.3 Purines, pyrimidines, nucleosides, and 22/44 50.0 nucleotides Central intermediary metabolism 11/23 47.8 Cellular processes 12/46 26.1 Cell envelope 32/140 22.8 Amino acid biosynthesis 2/19 10.5 Signal transduction 2/12 16.6 Unknown function 47/201 23.4 Transcription 7/31 22.6 Transport and binding proteins 20/119 16.8 DNA metabolism 14/81 17.3 Biosynthesis of cofactors, prosthetic groups, 14/88 15.9 and carriers Hypothetical proteins (includes conserved) 96/695 13.8 Regulatory functions 5/47 10.6 Other categories 2/134 1.5 aFunctional classification data obtained from TIGR (www.tigr.org) bSome proteins have been assigned to more than one functional class - To date, there is only one reported attempt to identify P. gingivalis proteins globally using a multidimensional proteomics approach(46). The present inventors have identified 478 P. gingivalis W50 proteins that were expressed during continuous culture under haem-limitation compared to the study of Zhang and co-workers(46) where 1014 P. gingivalis ATCC 33277 proteins were identified when this strain was cultured in keratinocyte growth medium and the same medium exposed to secreted epithelial cell components. As the strain used, the growth conditions and the processing of MS data were different in the two studies, it is difficult to make direct comparisons between the two datasets. Nevertheless, 75 proteins were uniquely identified in the present methods.
- Using CELLO to predict the subcellular protein localisation, most of the proteins identified in this study were predicted to be from the cytoplasm (347 out of a predicted 1350 proteins), followed by the periplasmic space (48/113), outer membrane (47/154), inner membrane (24/256) and extracellular (12/35). As expected, a low percentage of predicted inner membrane proteins were identified. To further increase the confidence of predicting inner membrane proteins the Transmembrane Hidden Markov Model (TMHMM) was used. Using the
TMHMM approach 20 out of the 242 proteins predicted to have >2 transmembrane domains (TMD) were identified and 5 out of 44 proteins predicted to have >10 TMDs were identified. Notably, all 12 of the membrane proteins with >10 transmembrane domains detected were identified from the in-solution digestion method. - Highly expressed genes in many bacteria often have a strong composition bias in terms of codon usage. The Codon Adaptation Index (CAD can be used to predict the expression level of a gene based on its codon sequence, with a higher CAI value indicating increased expression(47). Of 1685 genes in the P. gingivalis genome that have >100 codons, almost 92% have CAI values between 0.62 and 0.80 (
FIG. 2 ). Although this range is narrow compared with eukaryotic organisms(48) it is similar to the thermophile Thermoanaerobacter tengcongensis where 89% of the predicted genes have CAI values between 0.35 and 0.50(49). The CAI values of the genes encoding the 478 identified proteins in this study have a similar distribution to the theoretical proteome although there was a bias towards the detection of higher abundance proteins. Despite this bias, a number of proteins encoded by genes of very low CAI were identified. This result clearly exemplifies the problem of the large dynamic range of protein abundance in cells, showing it is currently not possible to detect all proteins at once. - The functional classes of proteins with the highest percentage of identified proteins are those involved in energy metabolism (Table 1), typically those involved in fermentation (95%, CAI 0.70-0.80), glycolysis (82%, CAI 0.71-0.83) and metabolism of amino acids and amines (81%, CAI 0.71-0.84). This was largely expected as essential proteins involved in basic metabolic functions such as energy metabolism have been shown to be very abundant in the bacterial cell. Most importantly almost 90% of these proteins are predicted to be in the cytoplasm, which also made detection easier compared with membrane proteins. The functional classes of proteins represented least are those involved in transpositioning, hypothetical proteins and regulatory functions.
- Although the complete genome of P. gingivalis has been sequenced, many critical questions regarding cellular functions remain unanswered. Proteomic studies that identify the translated gene products therefore help provide additional insights into the functional genome. For example P. gingivalis is known to be asaccharolytic(3) although the genome contains putative ORFs for all enzymes of the glycolytic pathway(43). The poor utilization of this pathway has been attributed to the glucose kinase gene being interrupted by an insertion element(43). In keeping with this finding glucose kinase, or another glycolysis-specific enzyme, phosphofructokinase was not identified. In contrast, all enzymes involved in gluconeogenesis were found, suggesting glucose necessary for processes such as polysaccharide biosynthesis may be derived via this pathway.
- 2.4 Response of P. gingivalis to Haem-Limitation as Determined Using ICAT
- To carry out the quantitative ICAT analysis of the P. gingivalis response to haem-limitation, the geLCMS approach was chosen, as the in-solution ICAT method was unsatisfactory due to the presence of strong interfering triply charged ions. The presence of these triply charged ions resulted in very low number of protein identifications. The ICAT labelled soluble and insoluble protein fractions were therefore independently separated by SDS-PACE and each gel lane divided into 20 sections for in-get tryptic digestion followed by affinity purification and LCMS. In total 142 proteins were identified. No matches to the reverse database were obtained indicating a low level of false positive identification. Considering proteins detected in both fractions, 53 proteins (34.0%) were identified based on the presence of two or more unique peptides with a probability based Mowse score corresponding to a p-value of at most 0.05, 60 proteins (38.5%) were identified based on the presence of one unique peptide identified from two or more different fractions or both ICAT labelling states (of those 58 have MASCOT score of ≧25) and 43 of the proteins (27.5%) were identified on the basis of a single unique peptide having a MASCOT score ≧25, expectation value of ≦0.01, a contiguous series of ‘b’ or ‘y’-type ions and the intense ions being accounted for, when interpreted manually. An example of a protein identification based on the analysis of a single unique peptide is shown in
FIG. 3 . - Of the proteins identified, 103 were found in the soluble fraction, 53 in the insoluble fraction and 14 proteins in both fractions. In response to the change in environmental conditions from haem-excess to haem-
limitation 70 of the identified proteins exhibited at least a two-fold change in abundance (FIG. 4 ). Of these, the abundance of 53 proteins increased more than 2 fold and the abundance of 17 proteins decreased more than 2 fold during haem-limitation. - In order to assess the reproducibility of the present data and to increase protein identification for the insoluble fractions, cells were harvested from the chemostat on different days during haem-limitation and excess growth. A different extraction method followed by ICAT labelling was then repeated with modified protocols (not shown). The data obtained were reproducible with proteins showing similar abundance ratios for selected proteins shown in Table 2 (e.g. PG0695 L/H=1.1, relabelling=1.3; PG0350 L/H=3.2, relabelling=2.6; PG0159 L/H=2.0, relabelling=2.2; PG0232 L/H=0.4, relabelling=0.4). To further verify the data, the relative abundance of those identified proteins that are predicted to be encoded by genes forming an operon were compared(50). Five groups of proteins were found to be encoded by predicted operons or by genes grouped at specific loci (Table 2—shaded). In each case the abundance of the encoded proteins appeared to be similar. One of the predicted operons encodes the outer membrane proteins, Omp40 (PG0694) and Omp41 (PG0695) whose abundance were unchanged at a ratio of 1.1 (haem-limitation/haem-excess, L/E). These proteins have high sequence similarity to the OmpA-like porins of Gram-negative bacteria(51) and are thought to provide a physical linkage between the outer membrane and the peptidoglycan layer. These structural proteins would not be expected to vary in abundance with a change in environmental haem levels. The remaining four predicted operons were found to be associated with glutamate or aspartate catabolism.
-
TABLE 2 Expression data of selected proteins in P. gingivalis during growth in haem-limitation Tigr Protein and peptide n- Fold SD No Acc# sequence identified Score1 N2 ICAT3 change4 (±) Proteinases 1 PG2024/ Arginine-specific protease 11 2 0.39 0.1 PG0506 (RgpACat/RgpB) .GQDEMNEILC*EK 51/14 .C*YDPGVTPK 24/14 2 PG2024/ Arginine-specific protease 19 3 0.95 0.2 PG0506 (RgpA/RgpB adhesins) .DAGMSAQSHEYC*VEVK 34/15 .EGLTATTFEEDGVAAG 44/13 NHEYC*VEVK .C*VNVTVNSTQFNPVK 59/15 3 PG0232 Zinc carboxypeptidase 4 1 0.40 0.1 .C*QILIENHDKR 21/18 .YPSLC*TTSVIGK 56/19 4 PG0026 Hypothetical protein 5 2 0.46 0.1 (Homology to Arg proteases) .C*VVNSPGGQTASMAK 30/14 .FSNLPVLGGESC*R 58/14 Invasion related proteins 5 PG0350 Internalin related protein 11 4 3.2 0.6 .FVPYNDDEGGEEENVC 35/13 *TTEHVEMAK .ILMELSEADVEC*TIK 46/14 .ILHC*NNNQLTALNLSA 23/15 NTK .LDLPANADIETLNC*SK 52/13 6 PG1374 Immunoreactive 47KDa 5 2 6.5 0.7 protein .GLSVLVC*IISNQIAGEE 27/15 MTK .NPNLTYLAC*PK 61/13 7 PG0159 Endopeptidase PepO 6 1 2.0 0.3 .METELAQIC*YSK 55/13 8 PG2132 Fimbrillin FimA 2 1 0.50 — .YDASNELRPTILC*IYGK 45/16 Iron transport and related proteins 9 PG1552 HmuR 1 1 4.0 — .MNSDELFEEITYPGYTIC*R 25/15 10 PG1019 Hypothetical protein 2 1 25.0 — .TYMIDTNDSENDC*IAR 70/14 11 PG1286 Ferritin 2 1 1.2 — .FGSVLEVFQQVYEHEC*K 73/13 12 PG0090 Dps family protein 3 1 1.1 0.1 .EEHELVC*AASTLK 36/13 13 PG0618 Alkyl hydroperoxide 1 1 41.6 — reductase subunit C 36/15 .AAQYVAAHDGQVC*PAK Others 14 PG0694 Omp40 5 1 1.1 0.1 .RPVSC*PECPEPTQPTVTR 26/16 15 PG0695 Omp41 12 1 1.1 0.1 .RPVSC*PECPEVTPVTK 39/15 1Highest scoring peptide score/threshold score (P = 0.05) 2Total number of independent peptide identification events for each protein 3Numbcr of unique ICAT labelled peptides identified for each protein 4Average ratios of all quantified peptides for each protein in fold change (Haem-limitation/excess) *Denotes ICAT modified cysteine - Three proteins possibly involved in invasion of host cells, internalin related protein (PG0350), immunoreactive 47 kDa protein (PG1374) and endopeptidase PepO (PG0159) were higher in abundance during haem-limitation (Table 2). During an antibiotic protection invasion assay P. gingivalis lacking a functional PG1374 had approximately 50% lower invasion capability into epithelial cells as compared to the wild type (W50, 32625±2582 cfu/mL, ECR312 16250±1089 cfu/mL; p<0.01, Student's T-test). In a separate binding assay, there is no significance difference in the adherence of the PG1374 mutant as compared to the wild type W50 (
FIG. 5 ). - PG1374 and PG0350 belong to a new class of cysteine containing protein with leucine rich repeat domains similar to the L. monocytogenes internalin protein. In1J(52). In L. monocytogenes, there are at least fifteen members of the internalin family and all have been found to share certain structural features consisting of a signal peptide, N-terminal leucine rich repeat domain followed by a conserved inter-repeat region. Many of these proteins are involved in the cellular invasion process(53). It has not been demonstrated why multiple internalins exist, but they are proposed to confer tropism toward different cell types(54).
- The higher abundance of PG1374 and PG0350 during haem limitation (6.5 and 3.2 fold increase respectively) in the current work suggests the expression of these two proteins is stimulated during low haem growth conditions. From the sequence information and predicted structure, more than half of the internalin LRR residues face outwards and are variable, suggesting them to be for protein-protein interaction surfaces specific to the different internalin classes(55). PG1374 and PG0350 both possesses a signal peptide and are part of the novel class of up to 34 cell surface-located outer membrane proteins that have no significant sequence similarities apart from a conserved C-Terminal Domain (CTD) of approximately 80 residues(56). In addition PG1374 is strongly immunogenic when probed with sera from human periodontitis patients(57) which further suggests it to be involved in cell surface protein interactions.
- The process of internalization of P. gingivalis into gingival epithelial cells is thought to involve a coordinated process of attachment and invasion mediated by fimbriae and a variety of cell surface proteinases(58-60). A P. gingivalis 33277 mutant lacking a functional putative internalin (PG0350) was shown to exhibit similar invasive characteristics but reduced biofilm formation capability compared to the wild type bacteria(46,61). The similar invasion was attributed to the presence of fimbriae that also play a role in epithelial cell invasion by strain 33277 although there is also a possibility that the similar invasiveness of this mutant was due to the presence of a second putative internalin protein (PG1374) encoded in the P. gingivalis genome. A double knockout of these two putative internalin proteins would potentially shed light on their possible cooperative invasive roles.
- The 50% reduction in epithelial cell invasion by ECR 312 and no difference in cell binding clearly demonstrate that the observed reduced invasion into epithelial cells by P. gingivalis deficient in PG1374 is not due to lesser adherence but a real defect in the invasion process (
FIG. 5 ). Bacterial invasion has been shown to be a highly complex process involving numerous proteins and receptors(62). The involvement of multiple factors involved in P. gingivalis invasion has been demonstrated by Lamont's group at the University of Florida and includes haloaeid dehalogenase, endopeptidases, a cation-transporting ATPase and an ATP-binding cassette transporter(60,63). The discovery of PG1374 as an epithelial cell invasion related protein therefore adds to the list of proteins involved in this complex host cell invasion process by bacterial pathogens. - For many bacterial pathogens, it has been well established that iron availability influences virulence and the invasion process, but little is known about the influence of haem on the expression of P. gingivalis invasion genes. We were unable to perform binding and invasion assay on haem-limited cells because of the high mortality rate of the P. gingivalis from the oxidative stress likely due to lack of the protective layer of the μ-oxo bis-haem form of iron PPIX(64-66). However in this study, we have shown that the levels of the putative invasion related proteins PepO, PG0350 and PG1374 increased under haem-limitation and PG1374 is involved in the cell invasion.
- These experiments described above are the first quantitative proteomic analysis of the response of P. gingivalis to a change in environmental conditions and demonstrates the utility of the stable isotope labelling approach combined with complete proteome analyses. P. gingivalis responds to limitation of the essential micronutrient haem by increasing the abundance of a number of proteins linked to the oxidative stress response, virulence and invasion of host cells.
- A P. gingivalis hypothetical protein, PG1019 was observed to be 25 times more abundant when the bacterium was grown under haem-limitation. Bioinformatic analyses suggest that PG1019 is a lipoprotein that is encoded by a gene located immediately upstream of a gene encoding a putative outer membrane receptor protein (PG1020) in a predicted operon. Multiple alignment (not shown) of PG1020 with known P. gingivalis TonB-linked outer membrane receptors shows the presence of a putative TonB box (residues 118-126), that is one of the characteristics of TonB-linked receptors(67) and a conserved region (residues 236-272) which Simpson and co-workers(68) refer to as the TonB box IV region. TonB-linked outer membrane receptors have been implicated with many iron, iron complex and other micronutrient uptake systems. The high abundance of PG1019 under haem limited growth conditions would be consistent with this protein being an accessory lipoprotein to a Ton-B linked system involved in the transport of iron/iron complexes into the cell or the sensing of environmental iron or iron complexes, although this remains to be demonstrated. In addition to the proteomic data a transcriptomic analysis using custom made P. gingivalis DNA microarrays of P. gingivalis W50 compared to a mutant lacking a function feoB1 gene (P. gingivalis FB1) was performed. The wild type W50 and FB1 mutant were both grown in continuous culture in haem excess conditions. P. gingivalis FB1 has approximately half the cellular iron content of the wild type W50(69). Genes that show an increase in transcription are therefore likely to be upregulated in response to the decrease in intracellular or environmental iron content. Both PG1019 and PG1020 were significantly upregulated to similar levels in the FB1 mutant compared to the wild type. PG1019 showed a
Log 2 increase of 2.46 and PG1020 showed aLog 2 increase of 2.33 at a significance level of P<0.05 in biological replicates, this is further evidence that these genes are located in an operon. Further a separate transcriptomic DNA microarray analysis of P. gingivalis W50 indicated that there was little or no expression of the PG1019 gene during haem-excess growth. - The most substantial change in P. gingivalis protein abundance during the transition from haem-excess to haem-limitation was observed with an alkyl hydroperoxide reductase protein, AhpC (PG0618, Table 2) which is a peroxide-scavenging enzyme that has been shown to play an important role in peroxide resistance in P. gingivalis (65). In P. gingivalis, formation of a layer of the μ-oxo bis-haem form of iron PPIX with oxygen on the cell surface is thought to act as an oxidative buffer due to its inherent catalase-like activity(11). This layer may also serve as a cell surface storage of iron and PPIX(70). During haem-limitation depletion of this source of iron PPIX was shown to result in an increased susceptibility to oxidative stress(64). The substantial increase in abundance of alkyl hydroperoxide reductase during haem-limitation could therefore be in response to the increased oxidative stress caused by the absence/reduction of the μ-oxo bishaem layer. OxyR an oxygen sensitive transcriptional activator also plays a role in the expression of alkyl hydroperoxide during anaerobic growth(71) where a P. gingivalis OxyR− mutant shows decrease of 16 fold in gene expression. More recently Duran-Pinedo and co-workers also demonstrated the positive regulation of aphC expression by the RprY response regulator. The substantial increase in abundance thus suggests haem availability may have a role in RprY and OxyR-controlled gene expression. Interestingly the very high Codon Adaption Index (CAI) value of this protein (0.838) suggests this protein is able to be highly expressed in the cell for rapid induction in response to such stress.
- Throughout this specification the word “comprise”, or variations such as “comprises” or “comprising”, will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.
- All publications mentioned in this specification are herein incorporated by reference. Any discussion of documents, acts, materials, devices, articles or the like which has been included in the present specification is solely for the purpose of providing a context for the present invention. It is not to be taken as an admission that any or all of these matters form part of the prior art base or were common general knowledge in the field relevant to the present invention as it existed anywhere before the priority date of each claim of this application.
- It will be appreciated by persons skilled in the art that numerous variations and/or modifications may be made to the invention as shown in the specific embodiments without departing from the spirit or scope of the invention as broadly described. The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive.
-
- 1. Albandar J M, Brunelle J A, Kingman A (1999). Destructive periodontal disease in
adults 30 years of age and older in the United States et al., 1988-1994. J. Periodontol. 70:13-29. - 2. Haffajec A D, Socransky S S (1994). Microbial etiological agents of destructive periodontal diseases, Periodontol. 2000 5:78-111.
- 3. Shah H, Gharbia S (1993). Batch culture and physiological properties. In: Biology of the species Porphyromonas gingivalis. Florida: Boca Raton CRC Press Inc, pp. 85-103.
- 4. Shizukuishi S, Tazaki K, Inoshita E, Kataoka K, Hanioka T, Amano A (1995). Effect of concentration of compounds containing iron on the growth of Porphyromonas gingivalis. FEMS Microhiol. Lett. 131:313-7.
- 5. Schifferle R E, Shostad S A, Bayers-Thering M T, Dyer D W, Neiders M E (1996). Effect of protoporphyrin IX limitation on Porphyromonas gingivalis. J. Endod. 22:352-5.
- 6. Dashper S G, Cross K J, Slakeski N, Lissel P, Aulakh P, Moore C, et al. (2004). Hemoglobin hydrolysis and haem acquisition by Porphyromonas gingivalis. Oral Microbial. Immunol. 19:50-6.
- 7. Shi Y, Ratnayake D B, Okamoto K, Abe N, Yamamoto K, Nakayama K (1999). Genetic analyses of proteolysis, hemoglobin binding, and hemagglutination of Porphyromonas gingivalis. Construction of mutants with a combination of rgpA, rgpB, kgp, and hagA. J. Biol. Chem. 274:17955-60.
- 8. Genco C A, Simpson W, Forng R Y, Egal M, Odusanya B M (1995). Characterization of a Tn4351-generated hernia uptake mutant of Porphyromonas gingivalis: evidence for the coordinate regulation of virulence factors by hemin. Infect. Immun. 63:2459-66.
- 9. Bramanti T E, Holt S C (1991). Roles of porphyrins and host iron transport proteins in regulation of growth of Porphyromonas gingivalis W50. J. Bacteria 173:7330-9.
- 10, Brochu V, Grenier O, Nakayama K, Mayrand D (2001), Acquisition of iron from human transferrin by Porphyromonas gingivalis: a role for Arg- and Lys-gingipain activities. Oral Microbiol. Immunol. 16:79-87.
- 11. Smalley J W, Silver J, Marsh P J, Birss A J (1998). The periodontopathogen Porphyromonas gingivalis binds iron protoporphyrin IX in the mu-oxo dimeric form: an oxidative buffer and possible pathogenic mechanism. Biochem. J. 331 (Pt 3):681-5.
- 12. Moore W E, Moore L V (1994). The bacteria of periodontal diseases. Periodontal. 2000 5:66-77.
- 13. Dashper S G, Hendtlass A, Slakeski N, Jackson C, Cross K J, Brownfield L, et al. (2000). Characterization of a novel outer membrane heroin-binding protein of Porphyromonas gingivalis. J. Bacterial. 182:6456-62.
- 14. Supek F, Vlahovicek K (2004). INCA: synonymous codon usage analysis and clustering by means of self-organizing map. Bioinformaties 20:2329-30.
- 15. Perbal J. (1984). A practical guide to molecular cloning, John Wiley and Sons (1984).
- 16, Sambrook J, Fritsch E F, Maniatis T. (1989), Molecular cloning: A laboratory manual, Cold Spring Habour Laboratory Press (1989).
- 17. Brown T A. (Editor) (1991). Essential Molecular Biology: A practical approach,
Volumes - 18. Glover M, Hames B D. (Editors) (1995 & 1996) DNA cloning: A practical approach, Volumes 1-4, IRL, Press (1995 and 1996),
- 19. Ausubel, F M. (Editor) (1988). Current protocols in Molecular Biology, Greene. Associates and Wiley-Interscience (1988, including all updates until present).
- 20. Devereaux J, Haeberli P, Smithies O, (1984), A comprehensive set of sequence analysis programs for the VAX. Nucleic Acids Res. 12: 387-395.
- 21. Needleman S B and Wunsch C D, (1970). A general method applicable to the search for similarities in the amino acid sequence of two proteins. J Mol. Biol. 48(3):443-53.
- 22. Thompson J D, Higgins D G, Gibson T J (1994). CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 1994 Nov. 11; 22(22):4673-80
- 23. Cox & Coulter (1992). In: Wong W K (ed.) Animals parasite control utilising technology. Bocca Raton; CRC Press, 49-112.
- 24. Paoletti E & Panicali D. Modified vaccinia virus. U.S. Pat. No. 4,603,112.
- 25. Stocker B A D. Non-reverting live vaccines. U.S. Pat. No. 5,210,035.
- 26. Stocker B A D. Live vaccines comprising two mutations and foreign antigen. U.S. Pat. No. 4,837,151.
- 27. Stocker B A D. Novel non-reverting Salmonella live vaccines. U.S. Pat. No. 4,735,801.
- 28. Curtiss R, III, Goldschmidt R M., Norah B. Fletehall and Sandra M. Kelly (1988) A virulent Salmonella typhimurium Δcya Δcrp oral vaccine strains expressing a streptococcal colonization and virulence antigen. Vaccine 6:155-160.
- 29. Jones P T, Dear, P H, Foote J, Neuberger M S, Winter G. (1986). Replacing the complementarity-determining regions in a human antibody with those from a mouse Nature 321:522-525.
- 30. Reichman L, Clark M, Waldman H, Winter G. (1988). Reshaping human antibodies for therapy. Nature 332: 323-327.
- 31. Carter P, Presta L, Gorman C M, Ridgway J B B, Henner D, et al. (1989). Humanization of an Anti-p185HER2 Antibody for Human Cancer Therapy. Proc. Natl. Acad. Sci. USA 89:4285-89.
- 32. Huse W D, Sastry L, Iverson S A, Kang A S, Alting-Mees M, et al. (1989). Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda. Science 246:1275-1281.
- 33. Li J, Steen H, Gygi S P (2003). Protein profiling with cleavable isotope-coded affinity tag (cICAT) reagents: the yeast salinity stress response. Mol. Cell. Proteomics 2:1198-1204.
- 34. Peng J, Elias J E, Thoreen C C, Licklider L J, Gygi S P (2003). Evaluation of multidimensional chromatography coupled with tandem mass spectrometry (LC/LC-MS/MS) for large-scale protein analysis: the yeast proteome. J. Proteome Res. 2:43-50.
- 35, Yu C S, Lin C J, Hwang J K (2004). Predicting subcellular localization of proteins for Gram-negative bacteria by support vector machines based on n-peptide compositions. Protein Sci. 13:1402-6.
- 36. Alm E J, Huang K H, Price M N, Koche R P, Keller K, Dubchak I L, et al. (2005). The MicrobesOnline Web site for comparative genomics. Genome. Res. 15:1015-22.
- 37. Fletcher H M, Schenkein H A, Morgan R M, Bailey K A, Berry C R and Macrina F L (1995). Virulence of a Porphyromonas gingivalis W83 mutant defective in the prtH gene. Infect Immun. 63:4:1521-1528.
- 38. Dashper S O, Brownfield L, Slakeski N, Zilm P S, Rogers A H, Reynolds E C (2001). Sodium ion-driven serine/threonine transport in Porphyromonas gingivalis. J. Bacteriol. 183:4142-8.
- 39, Lamont R J, Chan A, Belton C M, Izutsu K T, Vasel D, Weinberg A. (1995) Porphyromonas gingivalis invasion of gingival epithelial cells. Infect Immun. 63:1.0:3878-3885.
- 40. Pathirana R D, O'Brien-Simpson N M, Visvanathan K, Hamilton J A, Reynolds E C. (2007). Flow cytometric analysis of adherence of Porphyromonas gingivalis to oral epithelial cells. Infect Immun. 75:5:2484-2492.
- 41. Smalley J W, Birss A J, McKee A S, Marsh P D (1993). Haemin-binding proteins of Porphyromonas gingivalis W50 grown in a chemostat under haemin-limitation. J. Gen. Microbial. 139:2145-50.
- 42. McKee A S, McDermid A S, Baskerville A, Dowsett A B, Ellwood D C, Marsh P D (1986). Effect of hemin on the physiology and virulence of Bacteroides gingivalis W50. Infect. Immun. 52:349-55.
- 43, Nelson K E, Fleischmann, R D, DeBoy R T, Paulsen I T, Fouts D E, Eisen J A, et al. (2003). Complete genome sequence of the oral pathogenic Bacterium Porphyromonas gingivalis strain W83. J. Bacterial. 185:5591-601.
- 44. Eymann C, Dreisbach A, Albrecht D, Bernhardt J, Becher D, Gentner S, et al. (2004). A comprehensive proteome map of growing Bacillus subtilis cells. Proteomics 4:2849-76.
- 45. Guina T, Purvine S O, Yi E C, Eng J, Goodlett D R, Aebersold R, et al. (2003). Quantitative proteomic analysis indicates increased synthesis of a quinolone by Pseudomonas aeruginosa isolates from cystic fibrosis airways. Proc. Natl. Acad. Sci. USA 100:2771-6,
- 46, Zhang Y, Wang T, Chen W, Yilmaz O, Park Y, Jung I Y, et al. (2005). Differential protein expression by Porphyromonas gingivalis in response to secreted epithelial cell components. Proteomics 5:198-211.
- 47. Sharp P M, Li W H (1987). The codon Adaptation Index—a measure of directional synonymous codon usage bias, and its potential applications. Nucleic. Acids Res. 15:1281-95.
- 48. Washburn M P, Wolters D, Yates J R, 3rd (2001). Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat. Biotechnol. 19:242-7.
- 49. Wang J, Xue Y, Feng X, Li X, Wang H, Li W, et al. (2004). An analysis of the proteomic profile for Thermoanaerobacter tengcongensis under optimal culture conditions. Proteomics 4:136-50.
- 50. Price M N, Huang K H, Alm E J, Arkin A P (2005). A novel method for accurate operon predictions in all sequenced prokaryotes. Nucleic Acids Res. 33:880-92.
- 51. Veith P D, Talbo G H, Slakeski N, Reynolds E C (2001). Identification of a novel heterodimeric outer membrane protein of Porphyromonas gingivalis by two-dimensional gel electrophoresis and peptide mass fingerprinting. Eur. J. Biochem. 268:4748-57.
- 52. Sabet C, Lecuit M, Cabanes D, Cossart P, Bierne H. (2005). LPXTG protein IntJ, a newly identified internalin involved in Listeria monocytogenes virulence. Infect Immun. 73:10:6912-6922.
- 53. Marino M, Braun L, Cossart P, Ghosh P (2000). A framework for interpreting the leucine-rich repeats of the Listeria internalins. Proc Natl Acad Sci USA 97:8784-8788.
- 54. Dramsi S, Biswas I, Magnin E, Braun L, Mastroeni P, Cossart P (1995). Entry of Listeria monocytogenes into hepatocytes requires expression of inIB, a surface protein of the internalin multigene family. Mol. Microbiol. 16:251-61.
- 55. Schubert W D, Urbanke C, Zichm T, Beier V, Machner M P, Domann E, Webland J, Chakraborty T, Heinz D W. Structure of internalin, a major invasion protein of Listeria monocytogenes, in complex with its human receptor E-cadherin. Cell. 2002 Dec. 13; 111(6):825-836.
- 56. Seers C A, Slakeski N, Veith P D, Nikolof T, Chen Y Y, Dashper S G, Reynolds E C. (2006). The RgpB C-terminal domain has a role in attachment of RgpB to the outer membrane and belongs to a novel C-terminal-domain family found in Porphyromonas gingivalis. J. Bacteriol. 188(17):6376-86.
- 57. Ross B C, Czajkowski L, Hocking D, Margetts M, Webb E, Rothel L, et al. (2001). Identification of vaccine candidate antigens from a genomic analysis of Porphyromonas gingivalis. Vaccine. 19(30):4135-4142.
- 58, Lamont R J, Oda D, Persson R E, Persson O R (1992). Interaction of Porphyromonas gingivalis with gingival epithelial cells maintained in culture. Oral Microbial Immunol 7:364-367.
- 59. Chen T, Nakayama K, Belliveau L, Duncan M J (2001). Porphyromonas gingivalis gingipains and adhesion to epithelial cells. Infect. Immun. 69:3048-56.
- 60. Park Y, Yilmaz O, Jung I Y, Lamont R J (2004). Identification of Porphyromonas gingivalis genes specifically expressed in human gingival epithelial cells by using differential display reverse transcription-PCR. Infect. Immun. 72:3752-8,
- 61. Capestany C A, Kuboniwa M, Jung I-Y, Park Y, Tribble G D, Lamont R J. (2006). Role of the Porphyromonas gingivalis In1J Protein in Homotypic and Heterotypic Biofilm Development. Infect. Immun. 74:5:3002-3005.
- 62. Cossart P, Sansonetti P J (2004). Bacterial invasion: the paradigms of enteroinvasive pathogens. Science. 304:242-248.
- 63. Tribble G D, Mao S, James C E, Richard J. Lamont R J (2006). A Porphyromonas gingivalis haloacid dehalogenase family phosphatase interacts with human phosphoproteins and is important for invasion Proc. Nan Acad Sci USA 103:11027-11032.
- 64. Diaz P I, Rogers A H (2004). The effect of oxygen on the growth and physiology of Porphyromonas gingivalis. Oral Microbial. Immunol. 19:88-94.
- 65. Okano S, Shibata Y, Shiroza T, Abiko Y. (2006). Proteomics-based analysis of a counter-oxidative stress system in Porphyromonas gingivalis. Proteomics. 6(1):251-258.
- 66. Smalley J W, Birss A J, Silver J, (2000). The periodontal pathogen Porphyromonas gingivalis harnesses the chemistry of the mu-oxo bishaem of iron protoporphyrin IX to protect against hydrogen peroxide. FEMS Microbial Lett. 183(1):159-64.
- 67. Schramm E, Mende J, Braun V, Kamp R M (1987). Nucleotide sequence of the colicin B activity gene cba: consensus pentapeptide among TonB-dependent colicins and receptors. J. Bacterial. 169:3350-3357.
- 68. Simpson W, Olczak T, Genco C A (2000). Characterization and expression of HmuR, a TonB-dependent hemoglobin receptor of Porphyromonas gingivalis. J. Bacterial. 182:5737-5748.
- 69. Dashper S G, Butler C A, Lissel J P, Paolini R A, Hoffmann B, Veith P D, et al. (2005). A novel Porphyromonas gingivalis FeoB plays a role in manganese accumulation. J. Biol. Chem. 280(30):28095-28102.
- 70. Shah H N, Bonnett R, Mateen B, Williams R A (1979). The porphyrin pigmentation of subspecies of Bacteroides melaminogenicus. Biochem. J. 180:45-50,
- 71. Diaz P I, Slakeski N, Reynolds E C, Morona R, Rogers A H, Kolenbrander P E (2006). Role of oxyR in the oral anaerobe Porphyromonas gingivalis. J Bacterial 188:2454-2462.
- 72. Duran-Pinedo A E, Nishikawa K, Duncan M J (2007). The RprY response regulator of Porphyromonas gingivalis. Mol. Microbial. 64(5):1416
Claims (22)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2006903425 | 2006-06-27 | ||
AU2006903425A AU2006903425A0 (en) | 2006-06-27 | Porphyromonas gingivalis polypeptides useful in the prevention of periodontal disease | |
PCT/AU2007/000890 WO2008000028A1 (en) | 2006-06-27 | 2007-06-27 | Porphyromonas gingivalis polypeptides useful in the prevention of periodontal disease |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/AU2007/000890 A-371-Of-International WO2008000028A1 (en) | 2006-06-27 | 2007-06-27 | Porphyromonas gingivalis polypeptides useful in the prevention of periodontal disease |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/547,556 Division US8916166B2 (en) | 2006-06-27 | 2012-07-12 | Porphyromonas gingivalis polypeptides useful in the prevention of periodontal disease |
Publications (1)
Publication Number | Publication Date |
---|---|
US20100092471A1 true US20100092471A1 (en) | 2010-04-15 |
Family
ID=38845037
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/306,495 Abandoned US20100092471A1 (en) | 2006-06-27 | 2007-06-27 | Porphyromonas Gingivalis Polypeptides Useful in the Prevention of Periodontal Disease |
US13/547,556 Expired - Fee Related US8916166B2 (en) | 2006-06-27 | 2012-07-12 | Porphyromonas gingivalis polypeptides useful in the prevention of periodontal disease |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/547,556 Expired - Fee Related US8916166B2 (en) | 2006-06-27 | 2012-07-12 | Porphyromonas gingivalis polypeptides useful in the prevention of periodontal disease |
Country Status (6)
Country | Link |
---|---|
US (2) | US20100092471A1 (en) |
EP (1) | EP2038297A4 (en) |
JP (1) | JP2009544279A (en) |
AU (1) | AU2007264402B2 (en) |
CA (1) | CA2652957A1 (en) |
WO (1) | WO2008000028A1 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080175867A1 (en) * | 1999-12-24 | 2008-07-24 | Csl Limited | P. gingivalis antigenic composition |
US20100034908A1 (en) * | 1997-12-10 | 2010-02-11 | Csl Limited | Porphyromonas gingivalis polypeptides and nucleotides |
US20100209362A1 (en) * | 2007-07-12 | 2010-08-19 | Oral Health Australia Pty Ltd. | Biofilm Treatment |
US20100297179A1 (en) * | 2007-07-12 | 2010-11-25 | Stuart Geoffrey Dashper | Immunology Treatment for Biofilms |
US20110280880A1 (en) * | 2008-08-29 | 2011-11-17 | Eric Charles Reynolds | Prevention, treatment and diagnosis of p.gingivalis infection |
US8431688B2 (en) | 1997-04-30 | 2013-04-30 | The University Of Melbourne | Synthetic peptide constructs for the diagnosis and treatment of Periodontitis associated with Porphyromonas gingivalis |
US9125853B2 (en) | 2010-02-26 | 2015-09-08 | Oral Health Australia Pty Ltd | Treatment or prevention of infection |
US9366673B2 (en) | 2009-08-02 | 2016-06-14 | Sanofi Pasteur Limited | Porphyromonas gingivalis polypeptides |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009173558A (en) * | 2008-01-22 | 2009-08-06 | Gen Corp:Kk | Anti-canine periodontal disease composition |
CN103443627B (en) * | 2010-12-15 | 2015-11-25 | 新时代株式会社 | Periodontal pathogenic bacteria blood plasma or serum antibody titer detection kit |
US11951140B2 (en) | 2011-02-04 | 2024-04-09 | Seed Health, Inc. | Modulation of an individual's gut microbiome to address osteoporosis and bone disease |
US11844720B2 (en) | 2011-02-04 | 2023-12-19 | Seed Health, Inc. | Method and system to reduce the likelihood of dental caries and halitosis |
US11951139B2 (en) | 2015-11-30 | 2024-04-09 | Seed Health, Inc. | Method and system for reducing the likelihood of osteoporosis |
US11191665B2 (en) | 2011-02-04 | 2021-12-07 | Joseph E. Kovarik | Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being |
WO2012173244A1 (en) * | 2011-06-17 | 2012-12-20 | 国立大学法人東北大学 | Marker for use in detection of periodontopathic bacterium communicable between men and animals |
JP6310631B2 (en) * | 2011-10-18 | 2018-04-11 | サンスター株式会社 | Periodontal pathogen plasma or serum antibody titer kit |
US11642382B2 (en) | 2013-12-20 | 2023-05-09 | Seed Health, Inc. | Method for treating an individual suffering from bladder cancer |
US11826388B2 (en) | 2013-12-20 | 2023-11-28 | Seed Health, Inc. | Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation |
US11529379B2 (en) | 2013-12-20 | 2022-12-20 | Seed Health, Inc. | Method and system for reducing the likelihood of developing colorectal cancer in an individual human being |
US11839632B2 (en) | 2013-12-20 | 2023-12-12 | Seed Health, Inc. | Topical application of CRISPR-modified bacteria to treat acne vulgaris |
US11833177B2 (en) | 2013-12-20 | 2023-12-05 | Seed Health, Inc. | Probiotic to enhance an individual's skin microbiome |
US11672835B2 (en) | 2013-12-20 | 2023-06-13 | Seed Health, Inc. | Method for treating individuals having cancer and who are receiving cancer immunotherapy |
AU2022205389A1 (en) * | 2021-01-11 | 2023-07-13 | Keystone Bio, Inc. | Antigenic composition(s) and method(s) against porphyromonas gingivalis for the prevention and/or treatment of infection and/or diseases |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4603112A (en) * | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
US4735801A (en) * | 1982-09-07 | 1988-04-05 | Board Of Trustees Of Leland Stanford Jr. University | Novel non-reverting salmonella live vaccines |
US4837151A (en) * | 1980-05-19 | 1989-06-06 | The Board Of Trustees Of The Leland Stanford Junior University, Stanford University | Live vaccines comprising two mutations and foreign antigen |
US5210035A (en) * | 1980-05-19 | 1993-05-11 | Board Of Trustees Of Leland Stanford Jr. University | Non-reventing live vaccines |
US6528038B1 (en) * | 1996-03-29 | 2003-03-04 | The University Of Melbourne | Porphyromonas gingivalis antigens for the diagnosis and treatment of periodontitis |
US6962706B1 (en) * | 1999-03-01 | 2005-11-08 | The University Of Melbourne | Synthetic peptides containing protective epitopes for the treatment and prevention of periodontitis associated with porphyromonas gingivalis |
US20050288866A1 (en) * | 2004-02-06 | 2005-12-29 | Council Of Scientific And Industrial Research | Computational method for identifying adhesin and adhesin-like proteins of therapeutic potential |
US7341727B1 (en) * | 1996-05-03 | 2008-03-11 | Emergent Product Development Gaithersburg Inc. | M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5830710A (en) | 1988-09-08 | 1998-11-03 | University Of Florida | Cloned porphyromonas gingivalis genes and probes for the detection of periodontal disease |
WO1994027606A1 (en) | 1993-05-28 | 1994-12-08 | Unisearch Limited | Method of treating helicobacter pylori infection |
AU6983594A (en) | 1993-06-28 | 1995-01-17 | Lion Corporation | Composition for oral cavity |
US5475097A (en) | 1993-10-21 | 1995-12-12 | University Of Georgia Research Foundation, Inc. | Lysine-specific Porphyromonas gingivalis proteinase |
DE69432795T2 (en) | 1993-09-10 | 2004-04-29 | University Of Georgia Research Foundation, Inc. | PORPHYROMONAS GINGIVALIS ARGININE-SPECIFIC PROTEINASE-ENCODING SEQUENCES |
US5523390A (en) | 1993-09-10 | 1996-06-04 | University Of Georgia Research Foundation, Inc. | Porphyromonas gingivalis arginine-specific proteinase |
US6017532A (en) | 1993-09-10 | 2000-01-25 | University Of Georgia Research Foundation, Inc. | Porphyromonas gingivalis arginine-specific proteinase |
JPH0797395A (en) | 1993-09-28 | 1995-04-11 | Kyowa Medex Co Ltd | Peptides containing sequence of porphyromonas gingivalis cilium protein and its use |
US5948636A (en) | 1994-03-29 | 1999-09-07 | Kyowa Hakko Kogyo Co., Ltd. | DNA and host cells encoding a cell surface protein of porphyromonas gingivalis |
AUPN627595A0 (en) | 1995-10-30 | 1995-11-23 | University Of Melbourne, The | Diagnostics and treatments of periodontal disease |
AU742668B2 (en) | 1996-03-22 | 2002-01-10 | Morehouse School Of Medicine | Immunogenic compositions comprising porphyromonas gingivalis peptides and methods |
AUPO652897A0 (en) | 1997-04-30 | 1997-05-29 | University Of Melbourne, The | Synthetic peptide constructs for the diagnosis and treatment of periodontitis |
KR100603552B1 (en) * | 1997-12-10 | 2006-07-20 | 씨에스엘 리미티드 | Porphyromonas gingivalis polypeptides and nucleotides |
US8129500B2 (en) | 1997-12-10 | 2012-03-06 | Csl Limited | Porphyromonas gingivalis polypeptides and nucleotides |
AUPP083997A0 (en) | 1997-12-10 | 1998-01-08 | Csl Limited | Porphyromonas gingivalis nucleotides |
US6444799B1 (en) | 1997-12-31 | 2002-09-03 | Csl Limited | P. gingivalis polynucleotides and uses thereof |
GB9913437D0 (en) | 1999-06-09 | 1999-08-11 | Medical Res Council | Fusion proteins |
AUPQ485999A0 (en) | 1999-12-24 | 2000-02-03 | Csl Limited | P. gingivalis antigenic composition |
AUPQ718200A0 (en) | 2000-04-28 | 2000-05-25 | Csl Limited | Porphyromonas gingivalis recombinant proteins and truncations |
US6576226B1 (en) | 2000-11-17 | 2003-06-10 | Gary R. Jernberg | Local delivery of agents for disruption and inhibition of bacterial biofilm for treatment of periodontal disease |
GB2381449A (en) | 2001-10-31 | 2003-05-07 | Smithkline Beecham Plc | Oral hygiene compositions comprising an electron acceptor |
WO2005019249A2 (en) | 2003-08-15 | 2005-03-03 | University Of Florida | Identification of porphyromonas gingivalis virulence polynucleotides for diagnosis, treatment, and monitoring of periodontal diseases |
US20090169568A1 (en) | 2004-09-23 | 2009-07-02 | The University Of Melbourne | Antigenic Complex for the Diagnosis and Treatment of Porphyromonas Gingivalis Infection |
WO2008016385A2 (en) | 2006-01-20 | 2008-02-07 | The University Of Washington | Deacylase polypeptides, deacylase polynucleotides, and methods of use thereof |
WO2008124646A2 (en) | 2007-04-06 | 2008-10-16 | The Government Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Services | Use of amyloid proteins as vaccine scaffolds |
EP2175851B1 (en) | 2007-07-12 | 2013-05-15 | Oral Health Australia Pty Ltd | Biofilm treatment |
CA2693717A1 (en) | 2007-07-12 | 2009-01-15 | Stuart Geoffrey Dashper | Immunology treatment for biofilms |
ES2633738T3 (en) | 2008-08-29 | 2017-09-25 | Oral Health Australia Pty Ltd | Prevention, treatment and diagnosis of P. infection gingival |
JP2012530073A (en) | 2009-06-19 | 2012-11-29 | オーラル ヘルス オーストラリア ピーティーワイ リミテッド | Casein-derived protease inhibitor peptide |
-
2007
- 2007-06-27 US US12/306,495 patent/US20100092471A1/en not_active Abandoned
- 2007-06-27 JP JP2009516822A patent/JP2009544279A/en active Pending
- 2007-06-27 CA CA002652957A patent/CA2652957A1/en not_active Abandoned
- 2007-06-27 EP EP07719129A patent/EP2038297A4/en not_active Ceased
- 2007-06-27 WO PCT/AU2007/000890 patent/WO2008000028A1/en active Application Filing
- 2007-06-27 AU AU2007264402A patent/AU2007264402B2/en not_active Ceased
-
2012
- 2012-07-12 US US13/547,556 patent/US8916166B2/en not_active Expired - Fee Related
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4837151A (en) * | 1980-05-19 | 1989-06-06 | The Board Of Trustees Of The Leland Stanford Junior University, Stanford University | Live vaccines comprising two mutations and foreign antigen |
US5210035A (en) * | 1980-05-19 | 1993-05-11 | Board Of Trustees Of Leland Stanford Jr. University | Non-reventing live vaccines |
US4603112A (en) * | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
US4735801A (en) * | 1982-09-07 | 1988-04-05 | Board Of Trustees Of Leland Stanford Jr. University | Novel non-reverting salmonella live vaccines |
US6528038B1 (en) * | 1996-03-29 | 2003-03-04 | The University Of Melbourne | Porphyromonas gingivalis antigens for the diagnosis and treatment of periodontitis |
US7341727B1 (en) * | 1996-05-03 | 2008-03-11 | Emergent Product Development Gaithersburg Inc. | M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same |
US6962706B1 (en) * | 1999-03-01 | 2005-11-08 | The University Of Melbourne | Synthetic peptides containing protective epitopes for the treatment and prevention of periodontitis associated with porphyromonas gingivalis |
US20050288866A1 (en) * | 2004-02-06 | 2005-12-29 | Council Of Scientific And Industrial Research | Computational method for identifying adhesin and adhesin-like proteins of therapeutic potential |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8431688B2 (en) | 1997-04-30 | 2013-04-30 | The University Of Melbourne | Synthetic peptide constructs for the diagnosis and treatment of Periodontitis associated with Porphyromonas gingivalis |
US8841420B2 (en) | 1997-04-30 | 2014-09-23 | The University Of Melbourne | Synthetic peptide constructs for the diagnosis and treatment of periodontis associated with Porphyromonas gingivalis |
US20100034908A1 (en) * | 1997-12-10 | 2010-02-11 | Csl Limited | Porphyromonas gingivalis polypeptides and nucleotides |
US8129500B2 (en) | 1997-12-10 | 2012-03-06 | Csl Limited | Porphyromonas gingivalis polypeptides and nucleotides |
US8642731B2 (en) | 1997-12-10 | 2014-02-04 | Csl Limited | Porphyromonas gingivalis polypeptides and nucleotides |
US20080175867A1 (en) * | 1999-12-24 | 2008-07-24 | Csl Limited | P. gingivalis antigenic composition |
US8282933B2 (en) | 1999-12-24 | 2012-10-09 | Csl Limited | P. gingivalis antigenic composition |
US8784831B2 (en) | 1999-12-24 | 2014-07-22 | Csl Limited | P. gingivalis antigenic composition |
US8911745B2 (en) | 2007-07-12 | 2014-12-16 | Oral Health Australia Pty Ltd. | Immunology treatment for biofilms |
US20100209362A1 (en) * | 2007-07-12 | 2010-08-19 | Oral Health Australia Pty Ltd. | Biofilm Treatment |
US20100297179A1 (en) * | 2007-07-12 | 2010-11-25 | Stuart Geoffrey Dashper | Immunology Treatment for Biofilms |
US8241611B2 (en) | 2007-07-12 | 2012-08-14 | Oral Health Austrailia Pty. Ltd. | Biofilm treatment |
US20110280880A1 (en) * | 2008-08-29 | 2011-11-17 | Eric Charles Reynolds | Prevention, treatment and diagnosis of p.gingivalis infection |
US8871213B2 (en) * | 2008-08-29 | 2014-10-28 | Oral Health Australia Pty Ltd | Prevention, treatment and diagnosis of P. gingivalis infection |
US9518109B2 (en) | 2008-08-29 | 2016-12-13 | Oral Health Australia Pty Ltd | Prevention, treatment and diagnosis of P. gingivalis infection |
US10851138B2 (en) | 2008-08-29 | 2020-12-01 | Oral Health Australia Pty Ltd | Methods of preparing P. gingivalis antibodies |
US11572391B2 (en) | 2008-08-29 | 2023-02-07 | Oral Health Australia Pty Ltd | Antibodies for prevention, treatment and diagnosis of P. gingivalis infection |
US9366673B2 (en) | 2009-08-02 | 2016-06-14 | Sanofi Pasteur Limited | Porphyromonas gingivalis polypeptides |
US9125853B2 (en) | 2010-02-26 | 2015-09-08 | Oral Health Australia Pty Ltd | Treatment or prevention of infection |
Also Published As
Publication number | Publication date |
---|---|
WO2008000028A1 (en) | 2008-01-03 |
EP2038297A1 (en) | 2009-03-25 |
AU2007264402A1 (en) | 2008-01-03 |
CA2652957A1 (en) | 2008-01-03 |
JP2009544279A (en) | 2009-12-17 |
US20130236488A1 (en) | 2013-09-12 |
WO2008000028A8 (en) | 2009-07-16 |
US8916166B2 (en) | 2014-12-23 |
AU2007264402B2 (en) | 2012-09-20 |
EP2038297A4 (en) | 2010-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8916166B2 (en) | Porphyromonas gingivalis polypeptides useful in the prevention of periodontal disease | |
Olaya-Abril et al. | Characterization of protective extracellular membrane-derived vesicles produced by Streptococcus pneumoniae | |
Roier et al. | Intranasal immunization with nontypeable Haemophilus influenzae outer membrane vesicles induces cross-protective immunity in mice | |
Bartolini et al. | Recombinant outer membrane vesicles carrying Chlamydia muridarum HtrA induce antibodies that neutralize chlamydial infection in vitro | |
US20130202641A1 (en) | Immunology treatment for biofilms | |
Soriani et al. | Relevance of pili in pathogenic streptococci pathogenesis and vaccine development | |
JP2008546390A (en) | Genes of otitis media isolates of unclassifiable Haemophilus influenzae | |
RU2617399C2 (en) | Treatment or prevention of infection | |
KR20100063706A (en) | Immunogenic streptococcus proteins | |
AU2019404924A1 (en) | O-linked glycosylation recognition motifs | |
Tsolakos et al. | Identification of vaccine antigens using integrated proteomic analyses of surface immunogens from serogroup B Neisseria meningitidis | |
AU2011220335A2 (en) | Treatment or prevention of infection | |
Cho et al. | Extracellular vesicle-associated antigens as a new vaccine platform against scrub typhus | |
Frazer et al. | Vaccination with recombinant adhesins from the RgpA–Kgp proteinase–adhesin complex protects against Porphyromonas gingivalis infection | |
CN114423448A (en) | Vaccine compositions and methods for selecting antigens | |
US10166280B2 (en) | Polypeptides and immunizing compositions containing Bacillus polypeptides and methods of use | |
US10100093B2 (en) | Polypeptides and immunizing compositions containing Burkholderia polypeptides and methods of use | |
AU2013203250B2 (en) | Immunology treatment for biofilms | |
US20060198852A1 (en) | Collagen-binding MSCRAMMs of Bacillus anthracis and uses therefor | |
WO2011097688A1 (en) | Protein domains and uses therefor | |
Vågnes et al. | Sera from mice immunized with DNA encoding Porphyromonas gingivalis catalytic or adhesin part of HRgpA inhibit degradation of human fibronectin by HRgpA | |
Rigg et al. | The molecular cloning, nucleotide sequence and expression of an antigenic determinant from Porphyromonas gingivalis | |
Roier et al. | Intranasal Immunization with Nontypeable Haemophilus influenzae Outer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: THE UNIVERSITY OF MELBOURNE,AUSTRALIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DASHPER, STUART GEOFFREY;ANG, CHING SENG;VEITH, PAUL DAVID;AND OTHERS;REEL/FRAME:022066/0481 Effective date: 20081010 Owner name: ORAL HEALTH AUSTRALIA PTY LTD,AUSTRALIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:THE UNIVERSITY OF MELBOURNE;REEL/FRAME:022066/0506 Effective date: 20081111 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |